Cagrilintide Clinical Protocol

Clinical-education protocol for cagrilintide (Novo Nordisk development codes NN9838 / AM833), a long-acting amylin receptor agonist. This protocol documents the cagrilintide-monotherapy clinical profile for completeness given its scientific significance in the amylin pathway; current clinical relevance is primarily as the CagriSema combo component (see [[CagriSema Protocol]] — Wave 2 sibling protocol — for combo-product clinical detail). Cagrilintide-monotherapy is NOT FDA-approved as of 2026-05-13; Novo Nordisk has effectively paused cagrilintide-monotherapy development, progressing the compound primarily as the CagriSema combo component (REDEFINE Phase 3 program). The cagrilintide-monotherapy evidence base is anchored by the Phase 2 dose-finding trial (Lau 2021 Lancet PMID 34798060; NCT03856047) and by the cagrilintide-alone arm of the Phase 3 REDEFINE-1 trial (Garvey 2025 NEJM PMID 40544433; NCT05567796; approximately 11.8% body weight loss at 68 weeks at 2.4 mg weekly maintenance).

Pattern AA.marketing-claims — load-bearing precision (Editorial Framework §1.2.1). When this protocol references cagrilintide’s regulatory state, the load-bearing phrase is “investigational; monotherapy development paused; progressed primarily as CagriSema combo.” Cagrilintide-monotherapy is not approved-for-marketing-claims for any indication as of 2026-05-13. The phrase “FDA-approved” appears in this protocol only when referring to (a) FDA-approved class comparators (semaglutide Wegovy / Ozempic / Rybelsus; tirzepatide Zepbound / Mounjaro; pramlintide Symlin as the only FDA-approved-for-marketing-claims amylin analog), or (b) the CagriSema combo’s anticipated FDA submission status (NDA filed per Novo Nordisk public disclosures; cross-reference [[CagriSema Protocol]]).

Pattern Z.research-precision throughout. Cagrilintide-monotherapy development is described as “paused,” “progressed primarily as combo,” or “monotherapy Phase 3 not advanced” — factual research-state framing, not deficit-framed vocabulary (“abandoned” / “failed” / “shelved” / “highly experimental” / “fringe” are explicitly excluded; the cagrilintide-monotherapy track preserves regulatory optionality and is anchored by a peer-reviewed Phase 3 cagrilintide-alone arm).

Amylin-receptor mechanism class — not GLP-1 / GIP / glucagon. Cagrilintide is a long-acting amylin receptor agonist; the receptor pharmacology (calcitonin receptor + RAMP1/2/3 heterodimers generating AMY1/AMY2/AMY3) is mechanism-class-distinct from the GLP-1R single agonist class (semaglutide, liraglutide), the GLP-1/GIP coagonist class (tirzepatide), the GLP-1/glucagon dual class (survodutide), and the GLP-1/GIP/glucagon triagonist class (retatrutide). §1, §2, §4, §5, §6 are structured to reflect amylin-specific pharmacology — particularly the brainstem area postrema / nucleus tractus solitarii dominant satiety-signaling site, the postprandial glucagon suppression at pancreatic α-cells, and the calcitonin-receptor-heterodimer architecture that anchors §6 bone-biology surveillance considerations.

§9 Combination rules — heavily cross-referenced to [[CagriSema Protocol]]. Because cagrilintide’s current clinical relevance is via the CagriSema combo, the protocol’s combination-rules section reads primarily as a routing reference to the CagriSema combo-product protocol with the cagrilintide-monotherapy-specific framing scoped to within-amylin-class context (pramlintide adjacent-class comparator) and to the cagrilintide-as-standalone-component framing.

§10 Pattern Z calibration. Anchor 5 (off-label / extrapolation transparency) is the dominant calibration surface for cagrilintide-monotherapy today, framed as research-state-paused, NOT as bias-vocabulary deficit framing. Current clinical access to cagrilintide is primarily via the CagriSema combo product (anticipated FDA approval pending; cross-reference [[CagriSema Protocol]]); cagrilintide-monotherapy access is restricted to (a) historical clinical trial enrollment (REDEFINE-1 cagrilintide-alone arm, COMPLETED), (b) compounded preparations from research-chemical / international-sourcing channels operating outside the post-FDA-approval shortage-driven 503A/503B framework, (c) clinician-judgment off-label investigational use where the regulatory pathway supports it. Anchor 2 (compounded counseling) is reframed in §10.3 as pre-approval-compounding framing — structurally parallel to the Retatrutide protocol §10.3 calibration — NOT as 503A/503B shortage-period framing.

Table of Contents

1. Indication scope and patient phenotypes
2. Selection criteria (inclusion / exclusion / contraindications)
3. Pre-treatment workup
4. Initiation protocol
5. Maintenance protocol
6. Side-effect management
7. Plateau and non-response algorithm
8. Discontinuation and tapering
9. Combination rules
10. Patient counseling beats (Pattern Z calibration-anchor-compliant)
11. Source citations
12. Clinical decision tree

Appendices

• A. Verification gate
• B. Pattern discipline summary
• C. Self-audit findings

---

1. Indication scope and patient phenotypes

1.1 Purpose

This protocol documents the cagrilintide-monotherapy clinical profile for completeness given its scientific significance in the amylin pathway. Cagrilintide is the design-generation successor to pramlintide (Symlin; FDA-approved 2005 for T1D / T2D insulin-adjunct indication) — engineered with C18 fatty-diacid acylation for once-weekly subcutaneous dosing and substituted to prevent the amyloid fibrillation that limits native amylin’s drugability. The compound is mechanism-class-distinct from the incretin pathway (GLP-1, GIP) and from glucagon receptor agonism; its clinical effect is delivered via amylin receptor agonism at brainstem area postrema / nucleus tractus solitarii satiety-signaling sites and at pancreatic α-cell receptors mediating postprandial glucagon suppression.

Current clinical relevance is primarily as the CagriSema combo component (see [[CagriSema Protocol]] — Wave 2 sibling protocol — for combo-product clinical detail). Cagrilintide-monotherapy is NOT FDA-approved as of 2026-05-13; monotherapy development is paused. Novo Nordisk’s publicly disclosed pipeline prioritizes the CagriSema combo product (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose co-formulated; REDEFINE Phase 3 program; NDA filed per public disclosures) over a separate standalone cagrilintide NDA submission. The cagrilintide-monotherapy track is preserved at regulatory-optionality level; it is not the prioritized commercial trajectory.

What this protocol IS. A clinical-education reference for the cagrilintide-monotherapy profile — the amylin-receptor mechanism class, the Phase 2 dose-finding evidence base, the Phase 3 cagrilintide-alone arm of REDEFINE-1, the safety considerations specific to amylin receptor agonism (particularly the calcitonin-receptor-heterodimer-anchored bone-biology surveillance question), and the comparator-class framing within the broader Module 5 weight-management pharmacotherapy landscape. Clinicians use this protocol to (a) understand the amylin-receptor mechanism class for clinical-education purposes, (b) anchor cagrilintide-component understanding within the CagriSema combo-product clinical decisions covered in [[CagriSema Protocol]], (c) handle the comparatively narrow current clinical-access pathways for cagrilintide-monotherapy (CagriSema combo as the dominant current pathway; investigational-supply or compounded preparations as alternate pre-FDA-approval-as-monotherapy pathways).

What this protocol IS NOT. It is not a current-prescribing protocol for cagrilintide-monotherapy at the general clinical-population level. Current prescribing of cagrilintide-monotherapy is restricted because cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; the CagriSema combo (anticipated FDA approval) is the prioritized clinical access pathway and is covered in [[CagriSema Protocol]]. This protocol does not establish a prescribing recommendation for cagrilintide-monotherapy at the general clinical-population level.

Pattern R.1 enforcement at this section: the protocol opens with what cagrilintide IS (long-acting amylin receptor agonist; design-generation successor to pramlintide; CagriSema combo component) and with the clinical-education framing — not with regulatory deficits or with what cagrilintide is not. Pattern AA enforcement: every regulatory claim in this section carries the pre-FDA-approval-for-marketing-claims-as-monotherapy qualification, and the monotherapy-paused status is stated factually (per Novo Nordisk public disclosures), not as deficit-framed vocabulary.

Pattern R.2 enforcement: the indication scope is locked at the section-architecture-design step. The cagrilintide-monotherapy indication scope per the published trial program is chronic weight management in adults with obesity or overweight with weight-related comorbidity. Other Module 5 indication categories are addressed primarily via the CagriSema combo product (cross-reference [[CagriSema Protocol]]) or are research-state-incomplete at the cagrilintide-monotherapy level. This scope is locked here; downstream sections (workup, initiation, maintenance, AE, combination, counseling) are read through this scope.

Pattern Z.research-precision enforcement: throughout this protocol, the cagrilintide-monotherapy development status is described as paused / progressed primarily as combo / monotherapy Phase 3 not advanced — factual research-state framing. The protocol does NOT use abandoned / failed / shelved / highly experimental / fringe / discontinued vocabulary. The cagrilintide-monotherapy track is anchored by a peer-reviewed Phase 3 cagrilintide-alone arm (REDEFINE-1) and by a peer-reviewed Phase 2 dose-finding trial (Lau 2021); the research base is real, and the pause is a commercial-strategy decision by Novo Nordisk to prioritize the CagriSema combo product.

1.2 Indication scope per the published trial program (monotherapy-paused state)

The cagrilintide-monotherapy indication scope per the published trial program is narrow by comparison to the FDA-approved class comparators (semaglutide six FDA-approved indications; tirzepatide two FDA-approved indications) and to the active-development class comparators (retatrutide TRIUMPH ten-trial program; survodutide SYNCHRONIZE + LIVERAGE programs). Cagrilintide-monotherapy is anchored to:

1. Chronic weight management (CWM) — adults with obesity or overweight with weight-related comorbidity (the published trial-program scope). Anchored to Phase 2 dose-finding (Lau DCW et al. Lancet 2021 PMID 34798060; NCT03856047; n=706; 26 weeks; BMI ≥30 or ≥27 with comorbidity; six arms 0.3 / 0.6 / 1.2 / 2.4 / 4.5 mg cagrilintide weekly plus liraglutide 3.0 mg active comparator plus placebo) and to the Phase 3 cagrilintide-alone arm of REDEFINE-1 (Garvey WT et al. NEJM 2025 PMID 40544433; NCT05567796; cagrilintide-alone arm within the four-arm REDEFINE-1 trial; n≈853 in cagrilintide-alone arm of n=3,417 total; 68 weeks; 2.4 mg weekly maintenance dose). Effect-size anchors: Phase 2 dose-response across 0.3-4.5 mg arms produced approximately 6.0–10.8% body weight reduction vs approximately 3.0% with placebo (2.4 mg arm approximately 9.7%); Phase 3 cagrilintide-alone arm produced approximately 11.8% body weight loss at 68 weeks at 2.4 mg weekly maintenance. The trial-program enrollment phenotype was BMI ≥30 or BMI ≥27 with weight-related comorbidity, similar in structure to the semaglutide STEP-1 / STEP-3 / STEP-4 enrollment frame. Pattern AA.marketing-claims precision: this scope is the published trial-program scope, not an FDA-approved-indication scope; cagrilintide-monotherapy is not approved-for-marketing-claims for chronic weight management as of 2026-05-13.

2. Type 2 diabetes mellitus (T2D) — glycemic control via cagrilintide-monotherapy: research-state-limited. Mechanism rationale exists (postprandial glucagon suppression at pancreatic α-cells + slowed gastric emptying delaying postprandial nutrient appearance); the predecessor amylin analog pramlintide demonstrated approximately 40-60% postprandial glucose excursion reduction in T2D / T1D insulin-adjunct use (Singh-Franco D et al. Diabetes Obes Metab 2011 PMID 21199269 meta-analysis). However, no dedicated cagrilintide-monotherapy Phase 2 or Phase 3 T2D-glycemic-control trial has been publicly disclosed by Novo Nordisk. The T2D glycemic-control indication context for the cagrilintide compound is primarily progressed via the CagriSema combo product — REDEFINE-2 Phase 3 (Davies MJ et al. NEJM 2025 PMID 40544432; n=1,206; obesity + T2D) and the CagriSema Phase 2 T2D dose-finding (Frias JP et al. Lancet 2023 PMID 37364590) — both [[CagriSema Protocol]] scope.

3. Other Module 5 indication categories — research-state-incomplete at the cagrilintide-monotherapy level. Cardiovascular outcomes (no standalone cagrilintide CVOT; CagriSema REDEFINE-3 NCT05669755 RECRUITING is the combo-product CVOT — [[CagriSema Protocol]] scope); MASH / MASLD (mechanism-stage research direction; no dedicated cagrilintide-monotherapy MASH trial; CagriSema combo-product MASH context — [[CagriSema Protocol]] scope); CKD-in-T2D (no standalone cagrilintide kidney-outcomes trial; class-comparator semaglutide FLOW PMID 38785209 is the FDA-approved-indication anchor in the class); HFpEF + obesity (no cagrilintide-monotherapy or CagriSema HFpEF trial publicly disclosed); pediatric / adolescent (REDEFINE adolescent NCT05669742 RECRUITING is CagriSema combo scope — [[CagriSema Protocol]]); bone biology surveillance is a mechanism-class-specific research direction (§6.12 develops); addiction biology / alcohol-use-disorder is preclinical-signal-only research direction.

Cross-trial enumeration consistency (Pattern W). The cagrilintide-monotherapy trial program comprises two principal trials with cagrilintide-monotherapy arms: the Phase 2 dose-finding trial (NCT03856047; COMPLETED; PMID 34798060) and the Phase 3 REDEFINE-1 trial cagrilintide-alone arm (NCT05567796; COMPLETED; PMID 40544433). The Phase 1b combination study (NCT03600480; PMID 33894838) contained an exploratory cagrilintide-alone reference arm but the load-bearing trial-design intent was combo characterization; the cagrilintide-alone arm in this Phase 1b is supporting Phase 1 PK / safety reference, not a primary efficacy-anchor source. The Phase 1 PK studies (Andreasen 2020 PMID 32852869; Vrhovac Madunić 2022 PMID 35156012) characterize the pharmacokinetic basis for once-weekly dosing but are not efficacy trials. This enumeration is locked in §1.2 and reconciled across §3 workup, §4 initiation, §5 maintenance, §11 citations.

1.3 Phenotype-targeting taxonomy

Within the chronic weight management indication scope, the cagrilintide-monotherapy trial program enrolled the following phenotype profile (Lau 2021 Phase 2 + REDEFINE-1 cagrilintide-alone arm):

• Metabolic phenotype. The Phase 2 trial enrolled obesity with mixed insulin-resistance status; REDEFINE-1 enrolled obesity without T2D (T2D-positive obesity was enrolled in REDEFINE-2 CagriSema combo only — [[CagriSema Protocol]] scope). Cagrilintide-monotherapy primary-target phenotype: non-diabetic obesity or overweight with weight-related comorbidity (BMI ≥30 or BMI ≥27 with comorbidity).
• Adiposity distribution. The Phase 2 and Phase 3 cagrilintide-alone arms did not pre-specify visceral-vs-subcutaneous adiposity-distribution sub-stratification; the trial-enrolled phenotype is broadly representative of the obesity / overweight population at the BMI threshold.
• Appetite phenotype. Cagrilintide’s mechanism class (amylin-receptor-mediated central appetite suppression via brainstem area postrema / nucleus tractus solitarii) is mechanistically aligned with hyperphagia-dominant and slow-satiety-dominant appetite phenotypes. The trial program did not pre-specify appetite-phenotype sub-stratification.
• Energy-expenditure phenotype. Not pre-specified.
• Comorbidity load. Phase 2 trial enrollment permitted BMI ≥27 with at least one weight-related comorbidity (T2D excluded from Phase 2; REDEFINE-1 enrollment also non-T2D). Monocondition (non-diabetic obesity) was the dominant enrolled phenotype.
• Pharmacologic history. Prior weight-loss-pharm exposure was permitted with washout per trial protocols; prior amylin-analog exposure (pramlintide) was rare given pramlintide’s narrow market position.
• Life-stage modifier. Adult enrollment; reproductive-age females on contraception per trial protocol; no adolescent or pediatric cagrilintide-monotherapy trial as of 2026-05-13 (REDEFINE adolescent NCT05669742 is CagriSema combo — [[CagriSema Protocol]] scope).

Primary-target phenotype for cagrilintide-monotherapy: non-diabetic adult obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity. Secondary-target phenotype: obesity with T2D — research-state-limited at the cagrilintide-monotherapy level; primarily addressed via the CagriSema combo product. Tertiary / off-target phenotype: pediatric / adolescent; severe renal impairment; severe hepatic impairment; pregnancy; lactation — all research-state-incomplete or trial-program-excluded at the cagrilintide-monotherapy level.

1.4 Cross-reference to case construction

Worked clinical cases in this protocol are anchored to the trial-enrolled phenotype above. Given cagrilintide-monotherapy’s narrow current clinical-access scope (monotherapy paused; CagriSema combo as the dominant pathway), the worked-example construction in this protocol focuses on (a) the cagrilintide-component understanding within the CagriSema combo context, and (b) the comparatively narrow scenarios where cagrilintide-monotherapy is a clinical consideration (compounded preparations; investigational supply via legacy trial-enrollment pathways; clinician-judgment within the regulatory-optionality framing). The CagriSema combo-product worked clinical cases are properly the [[CagriSema Protocol]] scope.

1.5 Worked example — the §1.5 scenario for cagrilintide-monotherapy (the cagrilintide-alone consideration in the monotherapy-paused state)

A 48-year-old female presents with BMI 32, non-diabetic obesity, prior weight-loss attempts including 12 months on phentermine-topiramate (modest 5% loss with regain to current weight) and 8 months on liraglutide 3.0 mg (4% loss with regain after discontinuation due to GI tolerability). No T2D; HbA1c 5.6; no ASCVD; no MASH-suspect labs; no CKD (eGFR 92); no MTC / MEN-2 family history; no pancreatitis history; no gastroparesis; no active pregnancy; not planning conception (postmenopausal). She has heard about cagrilintide in the broader obesity-pharmacotherapy news cycle and is asking specifically about cagrilintide-monotherapy.

Indication-scope mapping (per §1.2). The patient’s phenotype matches the cagrilintide-monotherapy primary-target phenotype (non-diabetic obesity, BMI ≥30, prior weight-loss-failure with regain). She would have been enrollable in the Phase 2 dose-finding trial or in the cagrilintide-alone arm of REDEFINE-1 had they been recruiting. The trial-program effect-size anchor for her phenotype: Phase 2 2.4 mg arm approximately 9.7% at 26 weeks; Phase 3 cagrilintide-alone arm approximately 11.8% at 68 weeks at 2.4 mg.

Current-access-pathway framing (Pattern AA.marketing-claims precision). Cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; current clinical access to cagrilintide is primarily via the CagriSema combo product (cagrilintide 2.4 mg + semaglutide 2.4 mg; NDA filed with FDA per Novo Nordisk public disclosures; cross-reference [[CagriSema Protocol]] for combo-product current-access pathways). The cagrilintide-monotherapy track is paused; clinician-judgment access pathways include (a) compounded cagrilintide from research-chemical / international-sourcing channels (operating outside the 503A/503B post-FDA-approval shortage framework; §10.3 develops the Pattern Z.research-precision framing), or (b) clinician-judgment off-label investigational-supply use where regulatory pathways support it. The CagriSema combo is the dominant current pathway and the prioritized clinical access route; the cagrilintide-monotherapy consideration in this patient’s situation reduces to (1) “do you specifically want the amylin-mechanism alone, or are you open to amylin-plus-GLP-1?” and (2) “do you want investigational compounded sourcing, or are you open to the anticipated FDA-approved combo product?”

Comparator framing (anchored to §10.5 Anchor 4). The patient’s prior liraglutide intolerance suggests a within-class-alternative-mechanism consideration; cagrilintide’s amylin-mechanism is non-overlapping with the GLP-1R-mechanism class her liraglutide intolerance was anchored to. The CagriSema combo product would re-introduce a GLP-1R-mechanism component (via the semaglutide 2.4 mg) that may pose the same tolerability concern; cagrilintide-monotherapy would avoid the GLP-1R component but at meaningfully lower effect magnitude (approximately 11.8% cagrilintide-monotherapy vs approximately 22.7% CagriSema combo at 68 weeks per REDEFINE-1; vs approximately 14.9% semaglutide-monotherapy at 68 weeks per STEP-1). The Pattern Z anchor 4 multi-dimensional comparator framing applies — effect magnitude, mechanism class, regulatory status, GI tolerability profile, current-access pathway, cost — and the patient and clinician decide.

Pattern AA.marketing-claims framing applied to §1.5. The patient’s phenotype matches a published-trial-program enrollment phenotype; the effect-size anchors are peer-reviewed (Lau 2021 Lancet PMID 34798060; Garvey 2025 NEJM PMID 40544433). Cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; any clinician-judgment use is off-label / pre-approval and requires the Pattern Z anchor 5 framing per §10.6 (explicit off-label labeling, informed-consent acknowledgement, primary-source rationale). The CagriSema combo route is the prioritized clinical-access pathway per Novo Nordisk public disclosures and per the regulatory state of 2026-05-13.

Pattern Z.research-precision framing applied to §1.5. The cagrilintide-monotherapy development status is paused, progressed primarily as combo — factual research-state framing. The patient is not given abandoned / shelved / failed framing; the cagrilintide-monotherapy track is real, the evidence base is peer-reviewed, and the pause is a Novo Nordisk commercial-strategy decision documented in the company’s public pipeline disclosures.

---

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who cagrilintide-monotherapy is for, who it is not for, and who it must not receive cagrilintide-monotherapy. Given the monotherapy-paused state, this section is structurally narrower than the corresponding Section 2 for FDA-approved class comparators (semaglutide, tirzepatide). Selection criteria for cagrilintide-component understanding within the CagriSema combo context are covered in [[CagriSema Protocol]] §2 — this protocol’s §2 addresses cagrilintide-monotherapy-specific criteria.

Pattern R.1 enforcement: §2 opens with inclusion criteria — who cagrilintide-monotherapy IS for — before exclusions and contraindications. Pattern AA enforcement: contraindication framing anchors to (a) the class-level GLP-1 RA contraindications applied conservatively to the cagrilintide compound where the amylin-mechanism does not contradict the class-level rationale (e.g., MTC family history is applied conservatively to cagrilintide given the calcitonin-receptor-heterodimer architecture), and (b) the pramlintide adjacent-class precedent where applicable (pramlintide labeling does not carry an MTC contraindication; the pramlintide 2005-onward post-marketing experience is the closest adjacent-class clinical-evidence reference). Pattern Z.research-precision: contraindication framing avoids bias-vocabulary; the language is factual (“clinician-judgment conservative application of class-level precedent” rather than “highly cautioned” / “strongly avoided”).

2.2 Inclusion criteria — the trial-enrolled phenotype

Inclusion criteria for cagrilintide-monotherapy are stated as the population the Phase 2 dose-finding trial (NCT03856047) and the Phase 3 cagrilintide-alone arm of REDEFINE-1 (NCT05567796) enrolled.

Chronic weight management — the published-trial-program inclusion:

• Age ≥18 years (Phase 2 / Phase 3 trial enrollment lower bound).
• BMI ≥30 (obesity), OR BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, OSA; T2D excluded from Phase 2 and from REDEFINE-1 cagrilintide-alone arm enrollment).
• Documented prior weight-loss attempt with regain or maintenance failure (Phase 3 enrollment phenotype emphasis; Phase 2 enrolled with mixed prior-weight-loss-attempt history).
• Adjunct to diet and exercise — the trial protocol included a lifestyle-intervention background regimen.
• Pregnancy / lactation status: not pregnant; on contraception if reproductive-age per trial protocol.
• Trial-enrollment laboratory thresholds: standard chronic weight management trial enrollment labs (renal function, hepatic function, hematologic, no severe untreated comorbidity).

Pattern AA.marketing-claims precision: this inclusion frame is the published-trial-program inclusion, not an FDA-approved-indication inclusion frame. Cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; the trial-program inclusion is the load-bearing reference for clinician-judgment within-trial-population use considerations (e.g., investigational-supply off-label use or compounded preparation use; cross-reference §10.3 + §10.6 Pattern Z framing).

2.3 Relative exclusion criteria — clinician-judgment phenotype

Phenotypes where cagrilintide-monotherapy is not contraindicated but where benefit is uncertain, risk is elevated, or trial data are sparse:

• Severe gastroparesis or gastroparesis-predisposing comorbidity. Cagrilintide’s mechanism includes slowed gastric emptying via brainstem-mediated vagal output; established gastroparesis carries elevated anatomical and symptomatic worsening risk. Trial programs typically excluded severe gastroparesis (Phase 2 and Phase 3 cagrilintide-alone arm protocols).
• Active or recent (within 12 months) acute pancreatitis. Mechanism-stage research direction on amylin / pancreatic biology (§5.3) does not establish elevated pancreatitis risk in the trial-population data; conservative clinician-judgment posture for active or recent pancreatitis is to defer cagrilintide-monotherapy pending 12-month stability post-event, analogous to the class-level GLP-1 RA precautionary framing.
• Severe gastrointestinal disease (active IBD flare, severe GERD with esophagitis). Relative — class-typical GI AE profile may exacerbate.
• Severe renal impairment (eGFR <30) outside trial-enrolled range. Trial-program enrollment supported normal-to-moderately-impaired renal function; severe renal impairment is research-state-incomplete at the cagrilintide-monotherapy level.
• Severe hepatic impairment (Child-Pugh C) outside trial-enrolled range.
• Active eating disorder (anorexia nervosa, bulimia nervosa, BED with active purging). The appetite-suppression mechanism is clinically inappropriate in disordered eating; ARFID and BED-without-purging are clinician-judgment phenotypes routed to behavioral-health co-management.
• Active malignancy on therapy (other than MTC / MEN-2 — see §2.4 conservative application). Trial programs typically excluded active cancer; clinician-judgment with oncology co-management.
• Bone-fracture-risk-elevated phenotype (postmenopausal women with established osteoporosis; older men with osteopenia plus prior low-trauma fracture). The calcitonin-receptor-heterodimer architecture of the amylin receptor (§5.2 + §6.12) anchors a mechanism-stage research direction on long-acting amylin receptor agonism’s bone-biology implications; clinical-evidence-stage data at trial-population scope is research-state-incomplete (Phase 2 and Phase 3 cagrilintide-alone arm did not include load-bearing fracture-risk endpoints). Clinician-judgment conservative posture is to apply standard age- and risk-stratified DXA screening per USPSTF / NOF guidelines plus consideration of calcium and vitamin D adequacy.

2.4 Hard contraindications — class-level boxed-warning conservative application + labeled-contraindication framework

Cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; there is no cagrilintide-specific FDA-labeled contraindication framework as of 2026-05-13. The hard-contraindication framework applied in this protocol is (a) the GLP-1 RA class-level boxed-warning contraindication framework applied conservatively to cagrilintide given the mechanism-stage research direction on amylin / calcitonin-receptor biology (§5.2 develops), and (b) the pramlintide adjacent-class labeled-contraindication framework where applicable. Pattern AA precision: this is a clinician-judgment conservative application of class-level precedent, not a cagrilintide-specific FDA-labeled contraindication.

Conservative-application hard contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC). The GLP-1 RA class carries a class-wide FDA boxed-warning contraindication for MTC and MEN-2 based on rodent C-cell tumorigenicity signal. Cagrilintide is mechanism-class-distinct (amylin receptor heterodimer engaging calcitonin receptor + RAMPs) but the calcitonin-receptor-heterodimer architecture motivates conservative clinician-judgment application of the GLP-1 RA MTC contraindication framework to cagrilintide-monotherapy pending cagrilintide-specific regulatory characterization. Pramlintide-precedent context (Pattern Z.research-precision framing): pramlintide (FDA-approved 2005; 20+ years of post-marketing experience) does NOT carry an MTC contraindication in current FDA labeling — the pramlintide post-marketing experience is the longest-running real-world amylin-class C-cell surveillance reference and has not surfaced a major MTC signal. The cagrilintide-specific MTC framework is regulatory-state-pending; the conservative clinician-judgment posture is to apply the GLP-1 RA precedent.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same conservative-application framework as MTC.
• Severe prior pancreatitis history (severe acute or chronic). Conservative application of GLP-1 RA class-level precautionary framing; cagrilintide-monotherapy trial-population data does not establish elevated pancreatitis risk but the mechanism-stage research direction (§5.3) supports clinician-judgment conservative posture.
• Known serious hypersensitivity to cagrilintide or excipient. Standard biologic-product hypersensitivity framework.
• Pregnancy. Class-level conservative application of GLP-1 RA pregnancy-contraindication framing; pramlintide pregnancy data is the adjacent-class reference (Category C; insufficient human data). Cagrilintide-specific or amylin-class pregnancy-exposure data is not included in the Parker 2025 pooled GLP-1 RA regulatory pregnancy dataset (PMID 40329607); pregnancy discontinuation per §8.4 arithmetic.
• Lactation. Class-level conservative application; lactation-exposure data is research-state-incomplete; cagrilintide is not used during breastfeeding per current investigational-use protocols.

2.5 Worked example — selection criteria applied to the §1.5 patient

The §1.5 patient (48-year-old female, BMI 32, non-diabetic obesity, prior weight-loss-attempt history, postmenopausal):

• Inclusion criteria. Trial-enrolled phenotype match — BMI ≥30, non-diabetic obesity, prior weight-loss-attempt history. Inclusion criteria met for cagrilintide-monotherapy clinician-judgment consideration.
• Relative exclusion criteria. No severe gastroparesis; no recent acute pancreatitis; no severe GI disease; eGFR 92 (no severe renal impairment); no severe hepatic impairment; no active eating disorder; no active malignancy. Bone-fracture-risk-elevated phenotype: postmenopausal — apply standard age-stratified DXA screening per USPSTF guideline; calcium and vitamin D adequacy assessment; cagrilintide-specific bone-biology surveillance per §6.12 is research-state-incomplete and applied per clinician-judgment conservative posture (e.g., re-DXA at 24 months if baseline normal; re-DXA earlier if baseline osteopenia).
• Hard contraindications. No MTC / MEN-2 family history. No prior severe pancreatitis. No known cagrilintide hypersensitivity. Not pregnant or planning conception (postmenopausal). Not lactating. All hard contraindications cleared.

The §1.5 patient passes the §2.2 inclusion-criteria filter, has no §2.3 relative-exclusion barriers beyond the bone-biology surveillance consideration (handled at §3 pre-treatment workup), and clears the §2.4 conservative-application hard contraindications. She proceeds to §3 pre-treatment workup. The clinician-judgment access-pathway decision (CagriSema combo via the prioritized pathway, cagrilintide-monotherapy via compounded preparation or investigational supply, or alternative within-class consideration including semaglutide or tirzepatide) is anchored to §10 patient-counseling beats with Pattern Z calibration anchors enforced.

---

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup before cagrilintide-monotherapy initiation (in any clinical-judgment access-pathway scenario per §10.3 / §10.6 framing). Given cagrilintide-monotherapy’s pre-FDA-approval-for-marketing-claims state, this section is structured as a clinical-education reference for the pre-treatment workup anticipated for cagrilintide-monotherapy use; the cagrilintide-component-of-CagriSema-combo pre-treatment workup is the [[CagriSema Protocol]] §3 scope and uses the same panel infrastructure with semaglutide-component additions.

The cagrilintide pre-treatment workup is structured into the standard Module 5 panels (standard metabolic, diabetes-specific if T2D, organ-baseline thyroid / pancreas / ophthalmology, body-composition) plus a cagrilintide-specific bone-biology baseline panel (§3.7) reflecting the calcitonin-receptor-heterodimer-anchored mechanism-class research direction (§5.2 + §6.12). Pattern W cross-section consistency: every lab in §3.2–§3.8 reconciles with §5 maintenance monitoring intervals and with §6 AE-class management triggers.

3.2 Standard metabolic panel

Applies to every cagrilintide-monotherapy clinical-judgment-use scenario.

• Comprehensive metabolic panel (CMP). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Establishes hepatic and renal baseline.
• Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available.
• Fasting glucose and HbA1c. Establishes glycemic baseline; screens for undiagnosed prediabetes or T2D. Cagrilintide-monotherapy in T2D-positive patients is research-state-limited at the standalone-cagrilintide level (§1.2); identification of T2D at pre-treatment workup routes the patient toward CagriSema combo (the prioritized current-access pathway for cagrilintide-component use in T2D-positive obesity per [[CagriSema Protocol]]).
• Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference is the visceral-adiposity-distribution anchor.
• Blood pressure (seated, two readings, standardized). Baseline.

3.3 Diabetes-specific panel (if T2D-positive phenotype)

The cagrilintide-monotherapy trial program (Phase 2 NCT03856047 + Phase 3 cagrilintide-alone arm of REDEFINE-1 NCT05567796) excluded T2D-positive enrollment. T2D-positive obesity is primarily addressed via the CagriSema combo product (REDEFINE-2 PMID 40544432 — [[CagriSema Protocol]]). When a T2D-positive patient is considered for cagrilintide-monotherapy (clinician-judgment off-label use), apply the standard diabetes-specific panel:

• HbA1c, fasting glucose, fasting C-peptide. Distinguishes T2D from LADA; informs concurrent-agent considerations (insulin / sulfonylurea hypoglycemia management per §6.7).
• GAD-65 antibodies if LADA suspected.
• Diabetes complication screen if not recent: dilated retinal exam, urine albumin-to-creatinine ratio (UACR), monofilament / vibratory testing for diabetic neuropathy.

3.4 MASH-specific panel (if MASH risk profile)

MASH / MASLD at the cagrilintide-monotherapy level is research-state-incomplete (§1.2); the CagriSema combo-product MASH context is [[CagriSema Protocol]] scope. If MASH risk profile is present (T2D-positive obesity + elevated AST/ALT + central adiposity), apply the standard MASH-specific panel:

• AST, ALT, GGT, alkaline phosphatase, total and direct bilirubin.
• Platelet count (FIB-4 component).
• FIB-4 score. Stratifies fibrosis risk: low <1.3, indeterminate 1.3–2.67, high >2.67.
• Vibration-controlled transient elastography (VCTE / FibroScan) if FIB-4 indeterminate or high.
• Hepatitis B surface antigen + Hepatitis C antibody.
• Iron studies if indicated.

3.5 Kidney-specific panel (if borderline kidney function)

If baseline eGFR 30–60, apply the standard kidney-specific panel:

• Serum creatinine, eGFR; cystatin C-based eGFR if discordant.
• UACR.
• Urinalysis with microscopy.

3.6 CV-risk-specific panel (if ASCVD risk profile)

Cagrilintide-monotherapy CV outcomes evidence is research-state-incomplete (§1.2; no standalone cagrilintide CVOT). If ASCVD risk profile present:

• ECG (12-lead) baseline.
• High-sensitivity troponin if symptomatic baseline.
• NT-proBNP or BNP if HFpEF-suspect.
• Echocardiogram if HFpEF-suspect.

3.7 Organ-baseline panels — thyroid, pancreas, ophthalmology + bone-biology baseline (cagrilintide-specific)

Class-level pre-treatment workup applied conservatively to cagrilintide-monotherapy plus a cagrilintide-specific bone-biology baseline reflecting the calcitonin-receptor-heterodimer mechanism-class research direction (§5.2 + §6.12).

• Thyroid baseline. TSH at minimum; neck examination for thyroid nodules. If personal or family history of MTC or MEN-2 is identified at this step, this is a §2.4 conservative-application hard contraindication and the protocol does not initiate cagrilintide-monotherapy. Routine calcitonin screening is not generally recommended (the pramlintide adjacent-class post-marketing experience supports the absence of routine calcitonin monitoring; the cagrilintide-specific framework is regulatory-state-pending).
• Pancreas baseline. Serum lipase, serum amylase (lipase is more pancreas-specific). Triglycerides. Pancreatitis-history documentation per §2.4.
• Ophthalmology — dilated retinal examination. Standard age- and risk-stratified ophthalmology assessment. NAION class-context surveillance (semaglutide-specific signal per Hathaway 2024 PMID 38958939; tirzepatide signal absent per Lakhani 2025 PMID 40383360); cagrilintide-monotherapy NAION-signal characterization is research-state-incomplete (no published pharmacovigilance signal for cagrilintide-monotherapy as of 2026-05-13). Pre-treatment dilated retinal exam for any patient with known background diabetic retinopathy or visual-symptom history.
• Bone-biology baseline (cagrilintide-specific). Reflects the §5.2 + §6.12 mechanism-class research direction on the calcitonin-receptor-heterodimer-anchored bone-biology surveillance question. Apply standard age- and risk-stratified DXA per USPSTF / NOF guidelines (postmenopausal women age ≥65, or younger postmenopausal with risk factors; men age ≥70 or younger with risk factors; consider DXA earlier if baseline osteopenia or prior low-trauma fracture). Assess calcium and vitamin D adequacy (25-OH vitamin D level; calcium intake history). The pramlintide adjacent-class 2005-onward post-marketing experience has not surfaced a major bone-biology / fracture-risk signal; the cagrilintide-specific bone-biology surveillance framework is research-state-incomplete and is applied at clinician-judgment conservative posture. Pattern Z.research-precision framing: this is a mechanism-class-anchored research direction, not an established bone-biology signal.

3.8 Body-composition baseline

• BIA or DEXA for lean mass, fat mass, visceral adipose tissue (DEXA preferred).
• Hand-grip strength or sit-to-stand timed test for functional baseline (particularly for ≥65 age phenotype where sarcopenia risk during weight loss is a clinical concern).

3.9 Worked example — pre-treatment workup applied to the §1.5 / §2.5 patient

The §1.5 / §2.5 patient (48-year-old female, BMI 32, postmenopausal, non-diabetic obesity):

• Standard metabolic panel (§3.2): CMP, fasting lipid panel, fasting glucose + HbA1c (5.6 normal), weight + height + BMI + waist circumference, blood pressure.
• Diabetes-specific panel (§3.3): not applicable (non-diabetic).
• MASH-specific panel (§3.4): baseline AST/ALT from standard panel; FIB-4 calculation; FIB-4 <1.3 (low fibrosis risk) — no escalation to VCTE unless FIB-4 indeterminate or high.
• Kidney-specific panel (§3.5): not applicable (eGFR 92).
• CV-risk-specific panel (§3.6): ECG baseline given age 48 + postmenopausal; not requiring full HFpEF / troponin workup.
• Organ-baseline (§3.7): TSH; neck exam (no MTC family history per §2.5); serum lipase; baseline dilated retinal exam (no prior known retinopathy); bone-biology baseline (cagrilintide-specific): DXA scan (postmenopausal age 48 with risk-factor assessment — apply earlier-than-USPSTF-default DXA given the cagrilintide-specific mechanism-class research direction; baseline T-score for cagrilintide-monotherapy or CagriSema combo consideration), 25-OH vitamin D level, calcium intake assessment.
• Body-composition baseline (§3.8): DEXA scan (overlapping with bone-DXA where the practice’s DEXA scanner supports both bone-density and body-composition acquisition).

The patient passes pre-treatment workup. The bone-biology baseline anchors the §5 maintenance monitoring decision tree (re-DXA at 24 months if baseline normal; earlier re-DXA if baseline osteopenia or if cagrilintide-monotherapy maintenance approaches 18-24 months without prior bone-biology re-assessment). The protocol routes the patient to §4 initiation (cagrilintide-monotherapy clinician-judgment access-pathway scenario per §10.3 / §10.6) or to the [[CagriSema Protocol]] §4 (CagriSema combo-product access pathway — the prioritized current-access route).

Pattern W cross-check applied to §3.9. The labs listed above reconcile with §5 maintenance monitoring intervals (weight quarterly + lipid annual + AST/ALT annual + FIB-4 annual + TSH annual + bone-biology DXA at 24-month intervals or earlier per baseline). The §6 AE-management triggers reconcile to the same baseline-lab panel (lipase symptom-prompted; not scheduled-interval).

---

4. Initiation protocol

4.1 Purpose

Define the starting dose, titration schedule, and tolerability-management cadence for cagrilintide-monotherapy initiation. Section 4 is the time-sequenced action plan from Day 0 (first dose) through approximately Week 16 (target-dose attainment for the cagrilintide-monotherapy 2.4 mg weekly maintenance dose) — the period during which the patient transitions from naive to maintenance-stable.

Section 4 carries the Pattern AA.marketing-claims qualification throughout: the titration schedule below is the published-trial-program titration (Phase 2 NCT03856047 + REDEFINE-1 cagrilintide-alone arm NCT05567796), not an FDA-labeled titration schedule. Clinician-judgment access-pathway scenarios for cagrilintide-monotherapy use (§10.3 compounded preparations; §10.6 off-label investigational supply) apply this titration as the clinical-education reference framework.

4.2 Starting dose

Cagrilintide 0.3 mg subcutaneous once weekly. This is the lowest dose studied in the Phase 2 dose-finding trial (Lau 2021 PMID 34798060) and the trial-program starting dose for the cagrilintide-alone arm of REDEFINE-1 (Garvey 2025 PMID 40544433). The 0.3 mg dose is tolerability-priming — sub-therapeutic for weight-loss effect; the purpose is GI-AE attenuation prior to escalation.

4.3 Titration schedule

The standard cagrilintide-monotherapy titration schedule per the published trial program: 16-week titration to the 2.4 mg weekly maintenance dose.

• Week 1–4: 0.3 mg weekly (tolerability-priming starting dose).
• Week 5–8: 0.6 mg weekly.
• Week 9–12: 1.2 mg weekly.
• Week 13–16: 1.7 mg weekly.
• Week 17 onward: 2.4 mg weekly (target maintenance dose for cagrilintide-monotherapy per Phase 2 + REDEFINE-1 cagrilintide-alone arm).

Total titration period: 16 weeks to target dose, with Week 17 being the first target-dose week. The Phase 2 dose-finding trial supported the dose-response curve plateau at the 2.4 mg dose (4.5 mg incremental effect over 2.4 mg was modest; 2.4 mg supports favorable tolerability vs higher doses); the 2.4 mg dose was carried into Phase 3 cagrilintide-alone arm of REDEFINE-1.

Slow-titration option (clinician-judgment within trial-program reference). Each interval doubled — Week 1–8: 0.3 mg; Week 9–16: 0.6 mg; Week 17–24: 1.2 mg; Week 25–32: 1.7 mg; Week 33 onward: 2.4 mg. Total: 32 weeks to target dose. Used for patients with persistent moderate-severity GI AE at any standard-schedule step. Patient on slow titration is not on a different protocol; they are on the standard protocol with a stretched timeline.

Pattern AA.marketing-claims precision: the standard 16-week titration is the published-trial-program titration; clinician-judgment slow-titration is within-trial-program latitude. Neither is an FDA-labeled titration schedule (cagrilintide-monotherapy is not FDA-approved-for-marketing-claims).

4.4 GI tolerability management at each titration step

Cagrilintide GI AE profile peaks at each dose escalation and typically attenuates within 2–4 weeks at stable dose. Trial-program prevalence per Phase 2 (PMID 34798060) and REDEFINE-1 cagrilintide-alone arm (PMID 40544433): nausea, vomiting, decreased appetite, dyspepsia, constipation, eructation are the dominant AE categories; dose-responsive across the 0.3-4.5 mg Phase 2 dose range; discontinuation due to GI AE was within the class-typical range for chronic weight management pharmacotherapy.

• Nausea — first-line non-pharmacologic. Reduce meal size, slow eating pace, avoid greasy / high-fat meals, hydrate consistently.
• Nausea — first-line pharmacologic. Ondansetron 4 mg PRN; consider scheduled dosing for moderate-severity nausea. QT considerations with concurrent medications.
• Vomiting — assessment. Distinguish protocol-related vomiting (expected, attenuates) from acute-pancreatitis-suspect vomiting (severe abdominal pain, persistent, with lipase elevation) — §6.4 algorithm.
• Diarrhea / constipation. Bowel-pattern-specific management.
• Eructation. Reassurance and food-pairing adjustments are first-line; cagrilintide-specific eructation reporting is consistent with the class-typical incretin / amylin GI AE profile.
• Volumetric titration adjustment. Persistent moderate-to-severe GI AE at any step is the trigger for slow-titration (§4.3) — hold at current dose for an additional 2–4 weeks before next escalation, or step down to prior dose if tolerability does not stabilize.

4.5 Early monitoring cadence

The early-monitoring cadence is the contact frequency during the initiation period.

• Week 2 (post-first-dose tolerability check, telehealth or in-person).
• Week 5–6 (after first titration step to 0.6 mg, with weight and BP).
• Week 9–12 (mid-titration tolerability and adherence; weight + BP).
• Week 16–17 (target-dose attainment confirmation; transition to §5 maintenance cadence).

Contact modality is practice-specific. Escalation triggers for any contact: severe GI AE, suspected pancreatitis, suspected gallbladder event, significant unintended weight loss → in-person evaluation within 48 hours.

4.6 Worked example — cagrilintide-monotherapy initiation walkthrough applied to the §1.5 / §2.5 / §3.9 patient

The §1.5 / §2.5 / §3.9 patient (48-year-old female, BMI 32, postmenopausal, non-diabetic obesity, pre-treatment workup cleared):

Access-pathway context (Pattern Z anchor 5 framing per §10.6). Cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; the patient’s access pathway is either (a) CagriSema combo (the prioritized current-access pathway; cross-reference [[CagriSema Protocol]] §4 for combo-product titration), (b) compounded cagrilintide from research-chemical / international-sourcing channels (§10.3 framing; not 503A/503B shortage-period framework), or (c) clinician-judgment off-label investigational supply where regulatory pathway supports it. The §4 initiation walkthrough below assumes the patient and clinician have selected the cagrilintide-monotherapy access pathway through pathway (b) or (c) per the §10 shared-decision-making framework; the patient and clinician have completed informed-consent acknowledgement of off-label / pre-FDA-approval-for-marketing-claims use.

Starting dose. Cagrilintide 0.3 mg subcutaneous once weekly. Tolerability-priming dose.

Standard titration schedule (per §4.3). Week 1–4: 0.3 mg → Week 5–8: 0.6 mg → Week 9–12: 1.2 mg → Week 13–16: 1.7 mg → Week 17 onward: 2.4 mg.

Tolerability management at each step. First-dose (0.3 mg, Week 1) GI AE profile: nausea is the most common early AE — typically mild and self-limited within 5–7 days for many patients; moderate or persistent nausea triggers ondansetron 4 mg PRN and reinforcement of meal-size and meal-composition counseling. Escalation to 0.6 mg (Week 5) is a common challenge step — nausea recurrence on dose increase is anticipated and counseled-for; if moderate-severity persists beyond 2 weeks at 0.6 mg, hold for an additional 2–4 weeks before escalating to 1.2 mg (slow-titration de facto applied at this step). Subsequent escalations (1.2 mg → 1.7 mg → 2.4 mg) follow the same hold-if-needed logic.

Early monitoring cadence — cagrilintide-monotherapy. Week 2 (post-first-dose telehealth tolerability check), Week 5–6 (post-first-titration with weight and BP), Week 9–12 (mid-titration weight + BP + tolerability), Week 16–17 (target-dose attainment — weight + BP + transition to §5 maintenance cadence).

Pattern V effect-size anchoring at target dose. Phase 2 2.4 mg arm approximately 9.7% at 26 weeks (Lau 2021 PMID 34798060); REDEFINE-1 cagrilintide-alone arm approximately 11.8% at 68 weeks (Garvey 2025 PMID 40544433). Effect-size expectations for the §1.5 patient at the 2.4 mg target dose: anticipated trajectory of approximately 5-8% loss at Month 6 on target dose; approximately 10-12% loss at Month 12-18 on continued target dose, anchored to the trial-program-typical Phase 3 trajectory.

Pattern AA.marketing-claims framing in §4.6. The 16-week titration is the published-trial-program titration, not an FDA-labeled titration. Cagrilintide-monotherapy clinical-judgment use is off-label / pre-FDA-approval-for-marketing-claims. The §10 patient-counseling framework anchors the patient’s informed-consent context and the comparator framing across cagrilintide-monotherapy vs CagriSema combo vs FDA-approved class comparators (semaglutide, tirzepatide).

---

5. Maintenance protocol

5.1 Purpose

Define the post-titration, target-dose-attained operating state of the cagrilintide-monotherapy protocol: target dose, monitoring intervals, dose-adjustment triggers, and the transition between maintenance and discontinuation (§8) or non-response algorithm (§7). Section 5 is the longest operational phase for cagrilintide-monotherapy clinician-judgment use; for a patient who tolerates target dose and continues therapy, maintenance is open-ended for the duration of clinical benefit, subject to the cagrilintide-monotherapy regulatory state (paused; current access via compounded preparations or investigational supply).

5.2 Target dose

Cagrilintide 2.4 mg subcutaneous once weekly. This is the trial-program target dose carried from Phase 2 dose-finding to Phase 3 cagrilintide-alone arm of REDEFINE-1. The Phase 2 dose-finding trial demonstrated that incremental effect at 4.5 mg over 2.4 mg was modest while GI tolerability was less favorable at 4.5 mg; the 2.4 mg dose is the protocol-recommended maintenance dose for cagrilintide-monotherapy clinical-judgment use.

5.3 Monitoring intervals

Monitoring intervals for the cagrilintide-monotherapy maintenance phase:

• First year on 2.4 mg target dose: quarterly visits (Month 4, 7, 10, 13 from target-dose attainment at Week 17).
• Year 2+: every 6 months for stable patients.

Monitoring panel at each interval:

• Weight, BP, brief AE-and-adherence interview.
• Body-composition reassessment (BIA or DEXA quarterly in year 1, biannually thereafter).
• Indication-specific labs (lipid panel annually; HbA1c annually if T2D-positive; AST/ALT + FIB-4 annually if MASH risk profile).
• Bone-biology surveillance (cagrilintide-specific per §3.7 + §6.12): DXA at 24 months from initiation if baseline normal; earlier re-DXA if baseline osteopenia or if cagrilintide-monotherapy maintenance approaches 18-24 months without prior bone-biology re-assessment. Calcium + vitamin D adequacy reassessment annually.
• Class-level lipase if any abdominal-pain symptom report (symptom-prompted, not scheduled-interval).

5.4 Dose-adjustment triggers

Dose adjustment in the maintenance phase is driven by three trigger categories:

• Target-not-met. <5% weight loss at Month 6 on 2.4 mg target dose with documented adherence triggers transition to §7 non-response algorithm.
• Target-overshoot. Unintended weight loss below patient’s pre-specified target floor (e.g., BMI dropping below 22) triggers dose-down to 1.7 mg or to 1.2 mg with re-evaluation.
• AE-emergent. Persistent moderate-severity GI AE on 2.4 mg that does not respond to symptomatic management is the most common dose-down trigger — to 1.7 mg with reassessment at Month 3 (whether 1.7 mg maintains adequate weight-loss effect for the patient). Persistent bone-biology surveillance concern (e.g., interval DXA shows accelerated bone loss beyond age-expected trajectory) triggers reassessment per §6.12 + §8 discontinuation framework.

5.5 Worked example — cagrilintide-monotherapy maintenance walkthrough applied to the §1.5 / §2.5 / §3.9 / §4.6 patient

The §1.5 patient at Month 6 on cagrilintide 2.4 mg weekly maintenance:

• Weight trajectory. Lost 6.8 kg from baseline (approximately 7% of starting weight); on-trajectory for trial-program-typical 7-9% at Month 6 per Phase 2 / Phase 3 cagrilintide-alone arm.
• BP, lipids, FIB-4. No significant changes vs baseline; lipase normal (no abdominal pain); HbA1c stable at 5.5 (slight improvement from 5.6 baseline).
• Body-composition reassessment. DEXA: lean mass loss approximately 20% of total weight loss (within trial-program-typical range for unsupplemented weight loss; below the lean-mass-loss-concern threshold of approximately 25-30% that would trigger a lean-mass-stack consideration per §9.3).
• Bone-biology surveillance. No interval DXA scheduled at Month 6; next bone-biology DXA at Month 24 per §5.3 cadence (baseline normal). Calcium + vitamin D status reassessed; vitamin D supplementation continued at 2000 IU/day.

Dose-adjustment decision. No trigger met. Continue 2.4 mg weekly. Next visit Month 7 — same panel; quarterly cadence through year 1.

Pattern V effect-size framing. The patient’s trajectory matches the Phase 3 cagrilintide-alone arm trajectory (11.8% at 68 weeks). Cross-comparator context: had the patient selected CagriSema combo, the anticipated trajectory would have been higher (approximately 22.7% at 68 weeks per REDEFINE-1 combo arm — [[CagriSema Protocol]] §5 develops). The patient’s cagrilintide-monotherapy selection trade-off (lower effect magnitude in exchange for mechanism-specific amylin-only effect, GLP-1R-component avoidance, or other patient-anchored reasons per §10.5 comparator framing) is anchored at her §10.2 initiation conversation and her informed-consent context.

Pattern W cross-check at §5.5. Monitoring intervals above reconcile with §3 pre-treatment panel (every monitoring lab is established as a baseline lab) and with §6 AE-management algorithms (every AE-trigger lab is in the monitoring schedule). Lipase is symptom-prompted, not scheduled-interval, per the AC2-26-class precedent on not screening with low-specificity labs absent symptom.

---

6. Side-effect management

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the cagrilintide-monotherapy AE categories. Section 6 is structured by AE class with each addressed in a standard sub-structure: anticipatory framing, identification, severity grading, first-line management, escalation triggers, discontinuation triggers. The cagrilintide-monotherapy AE profile is broadly class-typical for incretin and amylin analog compounds (GI-dominant); the cagrilintide-specific AE-class subsection is §6.10 on bone-biology surveillance reflecting the calcitonin-receptor-heterodimer mechanism-class research direction (§5.2 + §6.10).

Pattern R: each AE-class sub-block opens with anticipatory framing — what the AE is, why it occurs, how common it is in the trial program — before management. Pattern V: when an AE-class signal is post-marketing or research-state-active, the signal status is documented precisely (post-marketing pharmacovigilance vs labeled warning vs labeled contraindication vs mechanism-stage research direction). Pattern AA: cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; the labeled-contraindication framework applied in this protocol is the conservative-application class-level framework per §2.4, not a cagrilintide-specific FDA-labeled-contraindication framework. Pattern Z.research-precision: AE-class framing avoids bias-vocabulary; signals under research-state evaluation are described factually.

6.2 GI AE class — the dominant AE class for cagrilintide-monotherapy

Anticipatory framing. Cagrilintide’s amylin-receptor-mediated mechanism produces a characteristic GI AE profile: nausea, vomiting, decreased appetite, dyspepsia, constipation, eructation, abdominal pain. The AE profile is peak-at-dose-escalation and typically attenuates within 2-4 weeks at stable dose. Trial-program prevalence per Phase 2 (Lau 2021 PMID 34798060): GI AEs dose-responsive across 0.3-4.5 mg arms; 2.4 mg arm GI AE incidence within the class-typical range for chronic weight management pharmacotherapy; titration over 2-6 weeks supported tolerability. REDEFINE-1 cagrilintide-alone arm safety reporting (Garvey 2025 PMID 40544433) extended the safety profile to the 68-week duration; specific incidence rates per primary publication.

Identification. Patient-reported during early-monitoring contacts (§4.5) and maintenance visits (§5.3). Standardized severity grading via CTCAE: Grade 1 (mild, intervention not indicated), Grade 2 (moderate, minimal intervention indicated), Grade 3 (severe, hospitalization indicated), Grade 4 (life-threatening). Most protocol-relevant GI AEs are Grade 1-2.

First-line management. Non-pharmacologic: meal-size reduction, slow eating pace, low-fat / non-greasy meal composition, hydration emphasis. Pharmacologic: ondansetron 4 mg PRN for nausea; loperamide PRN for diarrhea per standard dosing; osmotic laxative (polyethylene glycol) for constipation; reassurance and meal-pairing adjustments for eructation.

Escalation triggers. Grade 3 severity at any step. Persistent Grade 2 severity beyond 4 weeks at stable dose. Vomiting with severe abdominal pain (assess for pancreatitis — §6.4). Significant unintended weight loss exceeding the protocol’s target trajectory.

Discontinuation triggers. Grade 3 GI AE that does not resolve with dose-down. Patient preference (Pattern Z calibration: patient-preference-anchored, not clinician-override).

6.3 Gallbladder AE class

Anticipatory framing. GLP-1 RA-class association with cholelithiasis and cholecystitis has been demonstrated across the FDA-approved class-comparator trial programs (semaglutide STEP; tirzepatide SURMOUNT); the mechanism is attributed to weight-loss-rate-related bile-supersaturation and to direct effects on gallbladder motility. Cagrilintide-monotherapy trial-population gallbladder AE incidence reporting per Phase 2 and REDEFINE-1 cagrilintide-alone arm publications. Pattern V direction-of-effect: the gallbladder AE class is mechanism-stage research direction for cagrilintide-monotherapy specifically (the weight-loss-rate-related mechanism applies broadly across the chronic weight management pharmacotherapy class regardless of mechanism class).

Identification. Symptom-prompted — right upper quadrant pain, post-prandial colicky pain, fever-and-pain combination. Ultrasound is first-line imaging.

First-line management. Symptomatic gallstones with confirmed cholelithiasis and symptoms compatible with biliary colic: surgical consultation; laparoscopic cholecystectomy is the typical management trajectory. Protocol decision: temporary hold during peri-operative window; resume at maintenance dose post-cholecystectomy if no other contraindication.

Escalation triggers. Acute cholecystitis with systemic signs. Choledocholithiasis suspected.

Discontinuation triggers. Recurrent symptomatic gallstones post-cholecystectomy: clinician judgment for protocol continuation vs alternative-molecule transition (or transition to CagriSema combo or to non-cagrilintide weight-management pathway per §8 + §10).

6.4 Pancreatitis AE class

Anticipatory framing. Pancreatitis signal in amylin-class pharmacovigilance is research-state-incomplete for cagrilintide specifically. Cagrilintide-monotherapy trial-population pancreatitis incidence (Phase 2 + REDEFINE-1 cagrilintide-alone arm) was within the class-typical range for chronic weight management pharmacotherapy; no clinically distinguishable signal vs background incidence at trial-population scale. The mechanism-stage research direction on amylin / pancreatic biology (§5.3) anchors the §6.4 surveillance posture: amylin is co-secreted with insulin from pancreatic β-cells; long-acting amylin receptor agonism’s implications for acinar tissue biology and pancreatic exocrine function are mechanism-stage research questions. The class-comparator GLP-1 RA pancreatitis-signal literature (Wen 2025 PMID 40988099 meta-analysis) is the adjacent evidence base; pramlintide adjacent-class post-marketing experience has not surfaced a major pancreatic cancer or pancreatitis signal.

Identification. Symptom-prompted — persistent severe upper abdominal pain radiating to back, often with vomiting, often worse with food.

First-line management. Acute persistent severe abdominal pain with vomiting → immediate evaluation, lipase + amylase + CMP + CBC + lipid panel + abdominal imaging (CT or MRCP). Discontinue cagrilintide pending evaluation.

Escalation triggers. Confirmed acute pancreatitis → hospitalization, supportive management.

Discontinuation triggers. Confirmed acute pancreatitis attributable to the molecule (excluding alternative etiology — gallstones, hypertriglyceridemia, alcohol) → permanent discontinuation; transition to non-cagrilintide Module 5 alternative if indication continues. Pattern V direction-of-effect: cagrilintide-attributable acute pancreatitis case attribution requires alternative-etiology exclusion at the same standard as the GLP-1 RA class.

6.5 Ophthalmologic AE class — NAION class-context

Anticipatory framing. NAION (non-arteritic anterior ischemic optic neuropathy) signal class-context: documented for semaglutide per Hathaway 2024 (PMID 38958939) post-marketing retrospective cohort; signal absent for tirzepatide at the same analytic threshold per Lakhani 2025 (PMID 40383360). Pattern V class-differentiation: NAION class-differentiation is GLP-1R-class specific (semaglutide-positive, tirzepatide-negative); the cagrilintide-monotherapy mechanism class (amylin receptor agonism via calcitonin-receptor-heterodimer; mechanism-class-distinct from GLP-1R) is research-state-uncharacterized for NAION-signal at cagrilintide-monotherapy trial-population scale.

Identification. Acute monocular vision loss, typically painless, often altitudinal visual field defect. Optic disc edema on exam in acute phase. Differential includes GCA (arteritic AION), retinal vascular occlusion, optic neuritis.

First-line management. Urgent ophthalmology evaluation. Discontinue cagrilintide pending evaluation. ESR/CRP to rule out arteritic etiology.

Escalation triggers. Confirmed NAION → permanent discontinuation, ophthalmology co-management.

Discontinuation triggers. Confirmed NAION → permanent discontinuation of cagrilintide; clinician-judgment decision about cross-class transition (semaglutide carries the NAION class-context signal; tirzepatide signal-negative at the Lakhani 2025 threshold; cross-class direction-of-effect for cagrilintide-monotherapy in NAION-positive patient is research-state-uncharacterized).

6.6 Cardiovascular AE class

Anticipatory framing. Cagrilintide-monotherapy CV outcomes evidence is research-state-incomplete (§1.2; no standalone cagrilintide CVOT; CagriSema CV outcomes via REDEFINE-3 NCT05669755 RECRUITING is [[CagriSema Protocol]] scope). Trial-population CV safety reporting in Phase 2 (PMID 34798060) and REDEFINE-1 cagrilintide-alone arm (PMID 40544433) shows the standard chronic weight management trial CV safety profile; no major MACE signal at trial-population scale; heart rate observations consistent with class-typical findings. The class-comparator GLP-1 RA CV outcomes work (semaglutide SELECT HR 0.80 MACE reduction in obesity + CVD per Lincoff 2023 PMID 37952131; tirzepatide SURMOUNT-MMO Phase 3 active) is the adjacent FDA-approved-class evidence base.

Identification. New-onset arrhythmia symptoms; unexplained tachycardia; chest pain.

First-line management. Standard cardiac evaluation per symptoms.

Discontinuation triggers. Confirmed acute coronary syndrome → typically temporary hold during peri-event window; resume at maintenance dose post-stabilization if cardiology clearance.

6.7 Injection-site AE class

Anticipatory framing. Injection-site reactions (erythema, induration, pruritus, nodule) occur at the class-typical frequency for weekly subcutaneous peptide injectables. Lipohypertrophy with site rotation failure.

Identification. Patient-reported or visit-observed.

First-line management. Site-rotation reinforcement (abdomen, thigh, upper arm — alternate weekly). Topical hydrocortisone for pruritus.

Discontinuation triggers. Severe / systemic hypersensitivity is a §2.4 conservative-application hard contraindication and triggers permanent discontinuation.

6.8 Hypoglycemia AE class

Anticipatory framing — cagrilintide-monotherapy-specific (Pattern V favorable direction-of-effect). Cagrilintide-alone does not produce clinically significant hypoglycemia in trial populations. The amylin biology (postprandial glucagon suppression paired with reduced food intake; no β-cell insulin-stimulating mechanism shared with the GLP-1R class) supports a favorable hypoglycemia profile relative to the GLP-1 RA class. In CagriSema combo with semaglutide (which itself has minimal hypoglycemia risk as monotherapy at the chronic-weight-management dose), the hypoglycemia risk emerges primarily in concomitant insulin or sulfonylurea use via the semaglutide component — [[CagriSema Protocol]] §6.

Identification. Patient-reported hypoglycemia events; CGM data if available.

First-line management. For cagrilintide-monotherapy in T2D-positive patients on concurrent insulin or sulfonylurea (clinician-judgment off-label use given cagrilintide-monotherapy trial-program T2D-exclusion): reduce concurrent insulin / SU dose; reinforce hypoglycemia recognition counseling. The hypoglycemia risk profile for cagrilintide-monotherapy is meaningfully more favorable than for the GLP-1 RA class.

Discontinuation triggers. Hypoglycemia from cagrilintide is not a discontinuation indication; it is a dose-adjustment indication for the concurrent hypoglycemia-inducing agent.

6.9 Pregnancy and lactation considerations (Pattern Z anchor 3 — LEADS with research-state data)

Human pregnancy-exposure data. Cagrilintide-specific or amylin-class pregnancy-exposure data is not included in the Parker SE et al. 2025 (PMID 40329607) pooled GLP-1 RA regulatory pregnancy dataset. The Parker 2025 pooled review covers semaglutide, liraglutide, dulaglutide, and class-related GLP-1 RA compounds — incidence of congenital abnormalities appears relatively low in this pooled dataset with limited sample size and unplanned-pregnancy exposure context. Cagrilintide-specific trial-program unplanned-pregnancy exposure data emerges through primary publication and regulatory submission reporting of the Phase 2 and REDEFINE-1 cagrilintide-alone arm. Pramlintide adjacent-class pregnancy data is the closest within-amylin-class reference (Category C; insufficient human data per FDA labeling); pramlintide labeling does not include a Category-X-equivalent pregnancy contraindication.

Pharmacokinetic facts (post-research-state-lead). Cagrilintide elimination half-life approximately 7 days (168 hours); approximately 5 half-lives (approximately 35 days) for >95% pharmacokinetic clearance. Conservative pharmacodynamic margin: approximately 60-day pre-conception discontinuation window.

Standard practice framing. Discontinuation upon pregnancy awareness for cagrilintide-monotherapy users. Class-level conservative application of GLP-1 RA pregnancy-discontinuation framing (§2.4 conservative-application contraindication).

Animal data context. Class-level conservative application; cagrilintide-specific human pregnancy-exposure data is research-state-incomplete; the adjacent GLP-1 RA class human pooled data (Parker 2025) is the closest reference.

Post-discontinuation weight-regain trajectory. Cagrilintide-monotherapy weight-regain post-discontinuation evidence is research-state-incomplete (no SURMOUNT-4-equivalent cagrilintide withdrawal trial; the class-comparator GLP-1 RA discontinuation literature shows substantial weight regain on withdrawal per the broader class evidence base — e.g., STEP-4 semaglutide PMID 33755728 approximately two-thirds of lost weight regained by 12 months post-discontinuation).

Pattern Z anchor 3 compliance verification. This subsection LEADS with research-state data (Parker 2025 pooled GLP-1 RA pregnancy data + cagrilintide-specific trial-population data status + pramlintide adjacent-class reference). PK facts, animal data + class-level conservative-application contraindication, and post-discontinuation weight-regain trajectory appear AFTER the research-state lead, scoped as factual context. The patient’s reproductive-planning decision is patient-anchored.

6.10 Bone-biology surveillance — cagrilintide-monotherapy mechanism-class-specific AE class

Cagrilintide-specific AE class reflecting the calcitonin-receptor-heterodimer mechanism-class research direction (§5.2 cross-reference). This subsection is structurally distinct from the GLP-1 RA class canonicals and protocols (semaglutide, tirzepatide, retatrutide, survodutide); the mechanism-class basis for the bone-biology surveillance question is amylin-specific.

Anticipatory framing. The amylin receptor heterodimer engages the calcitonin receptor as the obligate non-RAMP subunit. Calcitonin is the dominant historical clinical regulator of osteoclast biology — used historically for hypercalcemia management and Paget’s disease. The shared calcitonin-receptor component raises a mechanism-stage research question: does long-acting amylin receptor agonism (or monomeric CTR cross-reactivity at therapeutic doses) modify bone turnover, calcium homeostasis, and fracture risk? Pramlintide adjacent-class data: pramlintide has been on the US market since 2005; post-marketing experience over 20+ years has not surfaced a major bone-biology or fracture-risk signal. Pramlintide’s structure differs from cagrilintide (non-acylated, short-acting); the pramlintide post-marketing experience is the closest adjacent-class reference but does not directly substitute for long-acting cagrilintide-specific data. Cagrilintide trial-population bone biology data: bone biology endpoints (DXA scans, biochemical bone turnover markers) in cagrilintide Phase 2 and REDEFINE-1 cagrilintide-alone arm are research-state-characterized at the standard chronic weight management trial protocol scope. Long-term bone biology surveillance is a research direction.

Identification. Trend in interval DXA T-score; biochemical bone turnover markers (CTX, P1NP) where clinically warranted; fracture history during cagrilintide-monotherapy maintenance.

First-line management. Standard age- and risk-stratified bone health monitoring per USPSTF / NOF guidelines applies to patients on cagrilintide-monotherapy as it would to patients not on cagrilintide-monotherapy. Calcium + vitamin D adequacy assessment. Cagrilintide-specific bone health monitoring beyond standard practice is research-state-incomplete; no cagrilintide-specific bone-biology contraindication or labeling recommendation as of 2026-05-13.

Escalation triggers. Interval DXA shows accelerated bone loss beyond age-expected trajectory; new low-trauma fracture during cagrilintide-monotherapy maintenance; new osteoporotic diagnosis on interval DXA → reassessment per §8 discontinuation framework or per clinician-judgment within the mechanism-class research direction.

Discontinuation triggers. Accelerated bone loss attributable to cagrilintide (excluding alternative etiology — calcium / vitamin D deficiency, glucocorticoid use, hyperparathyroidism) → clinician-judgment for protocol continuation vs alternative-molecule transition. The cagrilintide-bone-biology attribution requires the same alternative-etiology exclusion discipline as the §6.4 pancreatitis-attribution standard.

Pattern Z.research-precision framing. This subsection is a mechanism-class-anchored research direction. It is NOT a documented bone-biology signal at the cagrilintide-monotherapy trial-population level; the framing is factual research-state characterization. Pramlintide adjacent-class 2005-onward post-marketing experience supports the absence of a major bone-biology signal at the within-amylin-class level. The cagrilintide-specific bone-biology surveillance posture is clinician-judgment conservative application of the mechanism-class research direction.

6.11 Cancer-context surveillance

Standard age- and risk-stratified cancer screening per USPSTF / ACS guidelines applies to patients on cagrilintide-monotherapy. The amylin-specific cancer-context evidence base is substantially less developed than the GLP-1 RA cancer-context literature (§5 canonical develops the mechanism-stage research direction on MTC C-cell biology, pancreatic biology, bone-microenvironment-adjacent contexts). Personal or family history of MTC or MEN-2 — §2.4 conservative-application contraindication applies. Calcitonin level monitoring is not standard clinical practice for cagrilintide-monotherapy (pramlintide adjacent-class precedent supports the absence of routine calcitonin monitoring); clinicians may consider baseline + periodic calcitonin in patients with specific calcitonin-elevation risk factors. The CagriSema combo-product cancer-context framework inherits the GLP-1 RA class cancer-context considerations via the semaglutide component (Ko 2026 SR PMID 41359966) — cross-reference [[CagriSema Protocol]] §6 + [[Semaglutide Protocol]] for combo-context cancer-context framing.

6.12 Worked example — AE management walkthrough for the §1.5 / §2.5 / §3.9 / §4.6 / §5.5 patient

The §1.5 patient at Month 9 on cagrilintide 2.4 mg weekly maintenance, presenting with persistent moderate nausea (Grade 2, recurring 2-3 days after each weekly injection) and approximately 8 kg total weight loss from baseline (approximately 8% of starting weight, on-trajectory for the cagrilintide-monotherapy trial-program trajectory).

Protocol response. Anticipatory framing: this is within the cagrilintide-monotherapy trial-program-typical AE profile at the maintenance dose; the recurring 2-3-day post-injection pattern is consistent with the pharmacokinetic profile of weekly cagrilintide. First-line management: meal-size and meal-composition reinforcement; consider scheduled (not just PRN) ondansetron for the 2-3-day-post-injection window. Reassessment at Month 10 visit: if nausea remains Grade 2 and patient is on-trajectory for indication target (>5% weight loss at Month 6 achieved here at Month 9 with 8% loss), continue current dose; if Grade 2 nausea is unacceptable to patient (Pattern Z calibration: patient-preference-anchored, not clinician-override), dose-down to 1.7 mg with Month 12 weight-trajectory reassessment.

The same §1.5 patient at Month 18, presenting with new low-trauma left distal radius fracture after a low-velocity fall on outstretched hand. Interval DXA performed: T-score at lumbar spine has dropped from baseline -1.2 (osteopenia) to -2.4 (approaching osteoporosis threshold).

Protocol response. §6.10 bone-biology surveillance escalation trigger met: accelerated bone loss beyond age-expected trajectory. Alternative-etiology exclusion: calcium intake and 25-OH vitamin D status reassessed (vitamin D level 28 ng/mL — sufficient; calcium intake 1000 mg/day — sufficient); no glucocorticoid use; PTH normal; TSH normal. The bone loss is not attributable to alternative etiology at the cumulative-cause-exclusion level. Clinician-judgment decision per §6.10 discontinuation trigger: cagrilintide-bone-biology attribution as the working hypothesis; the mechanism-class research direction (§5.2 calcitonin-receptor-heterodimer architecture) supports the conservative-application posture. Clinician-judgment discontinuation of cagrilintide-monotherapy with §8 taper schedule per §8.3; transition to alternative weight-management approach — discussion includes (a) semaglutide alone (no bone-biology mechanism-class concern; the NAION class-context signal applies per §6.5 considerations); (b) tirzepatide (no bone-biology mechanism-class concern; favorable NAION signal per Lakhani 2025); (c) lifestyle / behavioral intensification without pharmacotherapy. Pattern Z framing: patient-preference-anchored selection across the alternatives, with each option’s effect-size and AE-profile presented multi-dimensionally per Anchor 4.

The same §1.5 patient at Month 4 (early in maintenance), presenting with acute severe upper abdominal pain radiating to back, vomiting, hospitalized in ED. Lipase elevated to 4× upper limit normal; abdominal CT shows mild peripancreatic fat stranding without necrosis. Triglycerides 180 mg/dL (normal). No gallstones on imaging. No alcohol history.

Protocol response. Confirmed acute pancreatitis; alternative etiologies (gallstones, severe hypertriglyceridemia, alcohol) excluded — cagrilintide-attributable acute pancreatitis is the working diagnosis per §6.4. Discontinue cagrilintide. Supportive pancreatitis management per standard of care. Permanent discontinuation of cagrilintide post-recovery per §6.4 discontinuation trigger; transition to non-amylin-class weight-management approach. Pattern V direction-of-effect: cagrilintide-attributable acute pancreatitis with alternative-etiology exclusion is the working diagnosis; case-attribution evidence at the mechanism-class level is research-state-active (mechanism-stage research direction on amylin / pancreatic biology per §5.3).

Pattern AA precision in §6.12. “Cagrilintide-attributable acute pancreatitis” is precise (alternative etiologies ruled out, temporal association); cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; the §6.4 discontinuation-trigger framework is the conservative-application class-level framework, not a cagrilintide-specific FDA-labeled framework. “Cagrilintide-bone-biology attribution” is precise (alternative etiologies excluded, interval-DXA-trajectory inflection); the mechanism-class research direction (§5.2 calcitonin-receptor-heterodimer) supports the conservative-application discontinuation posture.

---

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when the cagrilintide-monotherapy primary effect (weight loss) has not met its target or has stalled. Section 7 is the diagnostic-and-decision branch point: distinguish pseudo-plateau (apparent stall that is in fact normal-trajectory variation), true plateau (legitimate response stall requiring intervention), and non-response (insufficient initial effect from the start).

7.2 Pseudo-plateau vs true plateau vs non-response — diagnostic distinctions

Pseudo-plateau. Apparent stall in weight that is in fact within normal week-to-week variation, or reflects body-composition change (lean mass preservation with fat-mass continued loss), or occurs in the predictable trial-trajectory pattern (most weight-loss molecules show deceleration in months 6-9 even on continued effective therapy). Pseudo-plateau is recognized by trajectory-context — comparing patient curve to the trial-program-typical curve.

True plateau. Legitimate response stall — patient was responding, then response flattens or reverses. Recognized by trajectory inflection plus adequate observation window (typically 2-3 months at stable dose to confirm).

Non-response. Insufficient initial effect from the start. Recognized at Month 3-6 on target dose with effect substantially below the trial-program-typical effect for the patient’s phenotype.

7.3 Set-point reset framing

Weight-regulation physiology operates on a defended set-point. Weight loss into a new set-point window requires sustained pharmacologic and behavioral intervention; loss beyond the body’s defended range tends to recruit counter-regulatory responses (increased hunger signals, decreased energy expenditure — adaptive thermogenesis). True plateau in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. §10 counseling frames plateau as biological-equilibrium and as decision point for continuation, intensification, or maintenance-at-new-set-point.

7.4 Decision tree for cagrilintide-monotherapy plateau / non-response

1. Confirm adherence. Missed doses, injection-technique issues, dose-formulation issues (particularly relevant for compounded cagrilintide preparations per §10.3 framing) are common pseudo-non-response causes.
2. Confirm trajectory-context. Plot patient’s curve against the trial-program-typical curve for their phenotype (Phase 3 cagrilintide-alone arm 11.8% at 68 weeks median trajectory).
3. Confirm dose attainment. Is the patient on 2.4 mg target dose? If not, complete titration; reassess at Month 3 on target.
4. Reassess phenotype. Does the patient’s clinical picture support the trial-enrolled phenotype, or is the patient in an under-represented or out-of-trial phenotype? Pattern V direction-of-effect: for under-represented phenotypes, expected effect-size may be smaller, recalibrate target.
5. If true plateau / non-response confirmed at adequate observation window:
   • Transition to CagriSema combo product. The CagriSema combo’s incremental weight-loss effect beyond cagrilintide alone (REDEFINE-1: combo 22.7% vs cagrilintide-alone 11.8% vs semaglutide-alone 16.1% at 68 weeks) supports the within-mechanism-pathway intensification. Pattern AA: CagriSema NDA filed per Novo Nordisk public disclosures; FDA approval pending; cross-reference [[CagriSema Protocol]].
   • Transition to a different mechanism class — semaglutide monotherapy (STEP-1 14.9% at 68 weeks; FDA-approved Wegovy 2.4 mg); tirzepatide (SURMOUNT-1 22.5% at 15 mg; FDA-approved Zepbound 15 mg); other within-Module-5 alternative per §10.5 comparator framing.
   • Intensification of behavioral / nutritional / activity program. Behavioral intensification is effect-additive across the chronic weight management pharmacotherapy class.

7.5 Worked example — cagrilintide-monotherapy non-responder algorithm

The §1.5 patient at Month 9 on cagrilintide 2.4 mg, has lost 3 kg from baseline (approximately 3% of starting weight) — below the trial-program-typical Month 9 trajectory (cagrilintide-alone arm at Month 9 of the 68-week trial typically tracking 7-8% loss).

Algorithm walkthrough.

Step 1 — adherence. Patient reports 100% adherence; injection technique confirmed; compounded cagrilintide source (per §10.3 framing) verified via certificate of analysis. Adherence-confirmed pseudo-non-response is ruled out at the verifiable level.

Step 2 — trajectory-context. Patient’s curve at Month 9 (3% loss) is below the cagrilintide-alone arm Month 9 trajectory. Not on-trajectory.

Step 3 — dose attainment. Patient is on 2.4 mg target dose; no further titration available within cagrilintide-monotherapy labeled trial-program dose range (Phase 2 explored up to 4.5 mg; the 2.4 mg dose was selected for Phase 3 carryover; 4.5 mg incremental effect over 2.4 mg was modest and tolerability less favorable).

Step 4 — phenotype reassessment. Patient is non-diabetic obesity BMI 32 — within the trial-enrolled phenotype. Phenotype is trial-enrolled; effect-size expectation should be approximately 11.8% at 68 weeks per Phase 3.

Step 5 — non-response confirmed at adequate observation window; decision branches:

5a. Transition to CagriSema combo product. Mechanism rationale: the semaglutide component adds non-overlapping GLP-1R-mediated satiety signaling to the amylin-mechanism cagrilintide effect; REDEFINE-1 cagrilintide-alone arm 11.8% vs CagriSema combo arm 22.7% at 68 weeks demonstrates the additive effect. Pattern AA: CagriSema NDA filed; FDA approval pending; current-access pathway varies — cross-reference [[CagriSema Protocol]] §10.3 for combo-product access framing.

5b. Transition to tirzepatide. SURMOUNT-1 effect-size approximately 22.5% at 15 mg in non-diabetic obesity (Jastreboff 2022; FDA-approved Zepbound 15 mg). Pattern V direction-of-effect: tirzepatide effect is substantially higher than cagrilintide-monotherapy effect; the patient may achieve clinically meaningful weight loss on tirzepatide that did not materialize on cagrilintide-monotherapy.

5c. Transition to semaglutide monotherapy. STEP-1 effect-size approximately 14.9% at 68 weeks (FDA-approved Wegovy 2.4 mg). Modest improvement over cagrilintide-monotherapy effect-size; less than CagriSema combo or tirzepatide effect-size.

5d. Intensification of behavioral / nutritional / activity program while continuing cagrilintide-monotherapy or transitioning to one of 5a-5c. Behavioral intensification is effect-additive.

Pattern Z calibration anchor applied at §7.5. The decision among 5a / 5b / 5c / 5d is patient-anchored, not clinician-mandated. §10 counseling beats frame the options without steering — present the trial-program-anchored effect-size estimates for each option, present the trade-offs (cost, AE-profile, adherence-complexity, mechanism class, FDA approval status), and the clinician-patient decision is patient-preference-driven within the medically reasonable options.

---

8. Discontinuation and tapering

8.1 Purpose

Define when to stop cagrilintide-monotherapy, how to taper if indicated, and how to frame post-discontinuation expectations. Section 8 is the symmetric counterpart to §4 initiation: just as initiation has anticipatory framing for AE and adherence, discontinuation has anticipatory framing for post-discontinuation period and for the patient-clinician decision about whether and when to re-initiate or transition to alternative pathways (CagriSema combo per [[CagriSema Protocol]]; FDA-approved class comparators).

8.2 When to discontinue — discontinuation triggers

Discontinuation is indicated when one of the following emerges:

• Confirmed conservative-application contraindication discovery (new MTC diagnosis, new MEN-2 family-history identification, new pregnancy in CWM indication). §2.4 conservative-application hard contraindications.
• Severe AE attributable to cagrilintide (confirmed acute pancreatitis per §6.4; confirmed NAION per §6.5; severe hypersensitivity reaction; bone-biology-attributable accelerated bone loss per §6.10). §6 AE-class-specific discontinuation triggers.
• Indication remission or resolution (rare in CWM context).
• Patient preference. Patient-anchored discontinuation decision is legitimate; the protocol’s role is to inform, not override.
• Access barriers. Compounded cagrilintide preparations may have supply variability (§10.3 framing); investigational supply pathways may close. The patient and clinician anticipate access-pathway considerations within the cagrilintide-monotherapy regulatory state and may transition to the CagriSema combo product (the prioritized current-access pathway per [[CagriSema Protocol]]) or to FDA-approved class comparators if cagrilintide-monotherapy access becomes operationally infeasible.
• Pre-conception planning for reproductive-age patients on CWM indication: discontinuation with approximately 35-day pharmacokinetic-washout per §8.4 arithmetic plus class-level pre-conception margin.

8.3 How to taper — molecule-specific tapering considerations

For cagrilintide-monotherapy in CWM context: pharmacokinetic tapering (step-down dosing) is not pharmacologically required — the half-life-driven clearance is fixed kinetics. However, gradual dose reduction is the protocol-recommended pattern for two reasons:

1. Weight-regain trajectory smoothing. Abrupt discontinuation produces faster weight-regain than gradual reduction; gradual reduction allows behavioral adaptation.
2. AE-class symmetry. Some patients experience appetite-rebound or GI-pattern shifts on abrupt discontinuation; gradual reduction attenuates these.

The typical cagrilintide-monotherapy taper pattern: 2.4 mg → 1.7 mg for 4 weeks → 1.2 mg for 4 weeks → 0.6 mg for 4 weeks → discontinue. Total taper period approximately 12 weeks. Clinician-judgment within the published-trial-program reference, not FDA-labeled.

8.4 Pre-conception washout arithmetic — cagrilintide

Cagrilintide elimination half-life approximately 7 days (168 hours; per Andreasen 2020 PMID 32852869). Approximately 5 half-lives = approximately 35 days for >95% pharmacokinetic clearance. The pramlintide adjacent-class FDA labeling does not specify a Category-X-equivalent pre-conception window; the conservative-application class-level GLP-1 RA pre-conception window (semaglutide label specifies 8 weeks; the 35-day pharmacokinetic minimum plus conservative pharmacodynamic margin yields the 8-week conservative recommendation) is applied to cagrilintide-monotherapy per clinician-judgment conservative posture. Approximately 60-day pre-conception discontinuation window is the conservative-application clinical recommendation.

8.5 Post-discontinuation weight-regain framing

The trial-program data on post-cagrilintide-discontinuation weight regain is research-state-incomplete (no dedicated cagrilintide-monotherapy withdrawal trial as of 2026-05-13; no SURMOUNT-4-equivalent cagrilintide trial). The class-comparator GLP-1 RA discontinuation literature (STEP-4 semaglutide PMID 33755728 approximately two-thirds of lost weight regained by 12 months post-discontinuation) is the adjacent evidence base; the mechanism — set-point physiology and the defended-weight biology described in §7.3 — predicts that without pharmacologic support, the body’s counter-regulatory responses re-establish a higher equilibrium for the cagrilintide-mechanism-class as for the GLP-1R-mechanism-class.

§10 framing in counseling does not pathologize weight regain post-discontinuation; it frames the regain trajectory as the expected biological response. Patients considering discontinuation are counseled on the expected regain trajectory and on the re-initiation pathway or on the CagriSema combo transition pathway.

8.6 Re-initiation pathway

A patient who discontinued cagrilintide-monotherapy and is considering re-initiation: typically re-titration from the 0.3 mg starting dose is the protocol-recommended pattern — the tolerability re-priming is equivalent to initial titration; abrupt re-initiation at the prior target dose is not recommended due to GI AE recurrence risk. §4 titration applies. Indication confirmation per §1, selection-criteria re-screening per §2 (conservative-application contraindication re-check; bone-biology surveillance baseline re-assessment per §3.7), pre-treatment workup refresh per §3 if discontinuation period exceeded 12 months or new comorbidity emerged.

Alternative pathway: transition to CagriSema combo. A patient who discontinued cagrilintide-monotherapy may transition to the CagriSema combo product (anticipated FDA approval pending; cross-reference [[CagriSema Protocol]] §4 for combo-product initiation), which adds the semaglutide component to the cagrilintide mechanism and provides the higher-effect-magnitude combo experience. The CagriSema combo titration schedule is the [[CagriSema Protocol]] §4 scope.

8.7 Worked example — cagrilintide-monotherapy discontinuation scenarios

Scenario A — pre-conception planning. A 32-year-old female on cagrilintide-monotherapy 2.4 mg, Month 18 on target dose, has lost 12 kg (approximately 12% of starting weight, on-trajectory) and is planning conception in approximately 8 months. Counseling beat: discuss the approximately 60-day pre-conception discontinuation window (conservative-application class-level framing per §8.4); plan taper start approximately 5 months from now (12-week taper period per §8.3, then approximately 60-day post-discontinuation clearance window). Pattern Z anchor 3 framing applies — pregnancy-planning counseling presents pharmacokinetic facts (7-day half-life, 35-day pharmacokinetic clearance, 60-day conservative-application window) and post-discontinuation weight-regain trajectory (class-comparator GLP-1 RA literature; cagrilintide-monotherapy-specific data research-state-incomplete) without steering toward continuation or discontinuation; the patient’s reproductive-planning decision is patient-anchored.

Scenario B — patient-preference discontinuation at Month 24. A 58-year-old male on cagrilintide-monotherapy 2.4 mg, has lost 11 kg (approximately 11% of starting weight) and stabilized at the new weight for the last 6 months; reports tolerable but consistent mild GI AE profile and wishes to discontinue. Counseling beat: discuss the class-comparator GLP-1 RA discontinuation literature (STEP-4-anchored trajectory; cagrilintide-monotherapy-specific evidence research-state-incomplete); discuss the re-initiation pathway (§8.6) or the CagriSema combo transition pathway. Protocol taper: 2.4 mg → 1.7 mg × 4 weeks → 1.2 mg × 4 weeks → 0.6 mg × 4 weeks → off. Post-discontinuation monitoring at Month 3, 6, 12 with weight and BP.

Scenario C — confirmed acute pancreatitis (per §6.4 / §6.12 case). Permanent discontinuation. No taper — abrupt discontinuation appropriate given AE-attributable etiology. Transition to non-amylin-class weight-management approach per §10.5 comparator framing.

Scenario D — bone-biology-attributable accelerated bone loss (per §6.10 / §6.12 case). Clinician-judgment discontinuation with §8.3 taper. Transition to non-amylin-mechanism alternative — semaglutide, tirzepatide, or behavioral / lifestyle intensification per §10.5 + §10.6 framing.

Scenario E — new pregnancy on protocol. A 29-year-old female on cagrilintide-monotherapy 2.4 mg discovers pregnancy at approximately 6 weeks gestation. Cagrilintide-monotherapy is class-level conservative-application contraindicated in pregnancy (§2.4). Immediate discontinuation. Obstetrics co-management; the pharmacokinetic clearance window (approximately 35 days, with first-trimester exposure already occurred) is documented for the obstetrics record. Cagrilintide-specific human pregnancy-exposure data is research-state-incomplete; the patient’s individual data point contributes to the emerging trial-population unplanned-pregnancy dataset per §6.9 framing. Post-pregnancy and post-lactation, re-initiation decision per §1 indication and §2 selection-criteria reapplication, or transition to CagriSema combo (anticipated FDA approval status at time of reapplication) per [[CagriSema Protocol]] re-initiation pathway.

Scenario F — compounded cagrilintide source closure (access-barrier-driven discontinuation). A 52-year-old male on cagrilintide-monotherapy 2.4 mg via compounded preparation has been on therapy for 16 months. His compounding-pharmacy source has closed operations. Counseling beat: discuss the §8.6 re-initiation pathway via alternative compounded-pharmacy source (with §10.3 quality-criteria re-evaluation framework) OR the CagriSema combo transition pathway (anticipated FDA approval status; cross-reference [[CagriSema Protocol]] §4 for combo initiation including any informed-consent considerations at the combo-product regulatory state) OR transition to FDA-approved class comparators (semaglutide Wegovy 2.4 mg; tirzepatide Zepbound 15 mg) per §10.5 multi-dimensional comparator framing. The decision is patient-anchored; the protocol presents the options factually.

Pattern Z anchor 3 precision in §8.7. Pregnancy-planning counseling presents the 7-day half-life, the 5-half-life clearance arithmetic, the approximately 60-day conservative-application pre-conception window, and the class-comparator GLP-1 RA post-discontinuation weight-regain trajectory — facts that the patient uses to make her reproductive-and-treatment-planning decision. The protocol does not steer the patient toward continued pharmacotherapy by emphasizing weight-regain risk, nor toward discontinuation by emphasizing pregnancy-exposure risk. Both facts are presented; the patient decides.

---

9. Combination rules

9.1 Purpose

Define what stacks with cagrilintide-monotherapy, what is contraindicated in combination, and the rationale for each combination category. Section 9 is heavily cross-referenced to [[CagriSema Protocol]] because cagrilintide’s current clinical relevance is primarily as the CagriSema combo component. The cagrilintide-component-of-CagriSema-combo combination considerations (CagriSema + SGLT2 inhibitor for T2D + CKD context; CagriSema + insulin in T2D advanced; CagriSema + lean-mass-stack peptides) are properly the [[CagriSema Protocol]] §9 scope. This protocol’s §9 addresses (a) the within-amylin-class context (pramlintide adjacent-class comparator), (b) the cagrilintide-monotherapy + cross-Module-class combinations (lean-mass stacks; cross-class adjunct considerations), (c) contraindicated combinations, and (d) the CagriSema combo as the primary cagrilintide-combination vehicle.

Pattern W cross-section consistency: every combination in this section is reconciled with §2 (no patient enters a combination with a §2.4 conservative-application contraindicated agent), §6 (combinations cannot mask or exacerbate AE-class concerns established in §6), and §10 (counseling beats for combinations are anchored to Pattern Z calibration anchors).

9.2 Within-Module-5 combinations — primarily via the CagriSema combo product

The principal within-Module-5 combination involving cagrilintide is CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose subcutaneous weekly co-formulated) — the load-bearing current-access pathway for cagrilintide-component clinical use. Cross-reference [[CagriSema Protocol]] for combo-product comprehensive detail.

CagriSema mechanism rationale. Amylin co-released with insulin in physiologic glucose response; amylin analog modulates gastric emptying and central satiety via brainstem area postrema / nucleus tractus solitarii (mechanism complementary to GLP-1’s hypothalamic + hindbrain + vagal-afferent satiety signaling). The non-overlapping satiety pathways (hindbrain amylin vs hypothalamic GLP-1) are the pharmacological foundation for the additive weight-loss effect.

Trial-program effect-size. REDEFINE-1 (Garvey 2025 PMID 40544433): CagriSema combo arm approximately 22.7% weight reduction (adherent) / approximately 20.4% (treatment-policy estimand) vs cagrilintide-alone arm approximately 11.8% vs semaglutide-alone arm approximately 16.1% vs placebo approximately 2.3-3.0% at 68 weeks in non-diabetic obesity. REDEFINE-2 (Davies 2025 PMID 40544432): CagriSema combo in obesity + T2D — [[CagriSema Protocol]] §1 + §4 + §5 develop the combo-product detail.

Pattern AA.marketing-claims precision. Regulatory status as of 2026-05-13: CagriSema NDA filed with FDA per Novo Nordisk public disclosures; FDA approval pending. The combo-product current-access framing is the [[CagriSema Protocol]] §10.3 scope. Cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; CagriSema is anticipated-FDA-approval per the Novo Nordisk public pipeline.

Other within-Module-5 combination considerations for cagrilintide-monotherapy (clinician-judgment off-label use):

• Cagrilintide-monotherapy + SGLT2 inhibitor (T2D + CKD context). Hypothetical combination with mechanism-additive rationale (SGLT2 inhibitor adds glucose-osmotic-diuretic and kidney-protective effects; cagrilintide adds amylin-mediated postprandial glycemic and weight effects). Research-state-incomplete at the cagrilintide-monotherapy level; no dedicated trial. The CagriSema + SGLT2 combination context is [[CagriSema Protocol]] §9 scope.
• Cagrilintide-monotherapy + insulin (T2D advanced). Hypothetical clinician-judgment off-label use. The hypoglycemia profile for cagrilintide-monotherapy is favorable (§6.8); concurrent insulin dose adjustment is mechanism-class-relevant (amylin-mediated postprandial glucagon suppression + slowed gastric emptying may reduce insulin requirement). Pramlintide adjacent-class precedent supports approximately 50% mealtime insulin reduction at amylin-analog initiation in T1D/T2D insulin-adjunct use (pramlintide FDA-labeled framing).

9.3 Cross-Module combinations — lean-mass and body-composition stacks

Cross-Module combinations involve adding a peptide outside the amylin / GLP-1 / GIP / glucagon metabolic-axis family to address a complementary clinical objective.

• Cagrilintide-monotherapy + CJC-1295 / Ipamorelin (GH secretagogue stack). Mechanism rationale: CJC-1295 (GHRH analog) + Ipamorelin (GH secretagogue) elevates endogenous growth hormone pulsatility, supporting lean-mass preservation during caloric deficit. Module 5.6 Lean Mass canon documents the M5.6 v3 stack with phenotype targeting, IGF-1 monitoring, and AE-class considerations. Pattern Z anchor 5 (off-label / extrapolation transparency): CJC-1295 and Ipamorelin are not FDA-approved-for-marketing-claims for this indication; the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data. The lean-mass-stack consideration applies symmetrically to the CagriSema combo product (cross-reference [[CagriSema Protocol]] §9.3).

• Cagrilintide-monotherapy + Tesamorelin (visceral adiposity context). Mechanism rationale: Tesamorelin (GHRH analog; FDA-approved for HIV-associated lipodystrophy; off-label for visceral adiposity in non-HIV context) reduces visceral adipose tissue. Pattern AA precision: off-label-for-non-HIV-visceral-adiposity framing is explicit. Module 5.5 Tesamorelin canon documents trial-program data and off-label clinical use.

• Cagrilintide-monotherapy + MOTS-c (mitochondrial peptide). Mechanism rationale: MOTS-c is a mitochondrially-encoded peptide with metabolic-regulator activity in preclinical models. Pattern AA.marketing-claims precision: MOTS-c is investigational; the current evidence base is mechanism + animal + early human pharmacology; no Phase 3 trials.

9.4 Contraindicated combinations

• Cagrilintide-monotherapy + pramlintide concurrent. Within-amylin-class redundant; not indicated.
• Cagrilintide-monotherapy + standalone GLP-1 RA monotherapy (e.g., concurrent cagrilintide-monotherapy with separate semaglutide or tirzepatide injection). Mechanistically duplicative of CagriSema combo (which is the fixed-dose co-formulation); the patient should be on CagriSema combo (the prioritized current-access pathway per [[CagriSema Protocol]]) rather than ad-hoc cagrilintide + GLP-1 RA combination. Pattern V: ad-hoc cagrilintide + GLP-1 RA combinations are research-state-uncharacterized at the safety and efficacy levels relative to CagriSema’s controlled co-formulation.
• Cagrilintide-monotherapy + DPP-4 inhibitor. Not contraindicated by safety; mechanistically not complementary (DPP-4 inhibitor extends endogenous GLP-1 / GIP; not mechanistically additive with amylin-receptor agonism in a way that supports clinical-rationale combination).
• Cagrilintide-monotherapy + concurrent sulfonylurea at full dose. Relative — sulfonylurea-induced hypoglycemia in T2D-positive cagrilintide-monotherapy users requires concurrent sulfonylurea dose-reduction per §6.8.

9.5 Worked example — cagrilintide-monotherapy combination scenarios

Scenario A — cagrilintide-monotherapy non-responder transitioning to CagriSema combo. The §7.5 patient (cagrilintide-monotherapy non-response at Month 9) elects pathway 5a (transition to CagriSema combo). Operational framing: discontinue cagrilintide-monotherapy with appropriate taper or immediate transition per clinician-judgment; initiate CagriSema combo per [[CagriSema Protocol]] §4 (combo titration schedule); semaglutide component carries class-level GLP-1 RA contraindications + pre-treatment workup considerations specific to the GLP-1R class (e.g., NAION class-context per §6.5); CagriSema regulatory status (anticipated FDA approval pending) governs the access-pathway considerations for combo-product use. Pattern AA precision throughout.

Scenario B — cagrilintide-monotherapy + M5.6 v3 lean-mass-stack. A 47-year-old male, baseline BMI 36, on cagrilintide-monotherapy 2.4 mg, Month 12 on target dose, has lost 14 kg with DEXA showing approximately 28% of lost mass as lean mass (above the 20-25% typical proportion for unsupplemented weight loss). Add M5.6 v3 stack — CJC-1295 + Ipamorelin per M5.6 stack protocol with IGF-1 monitoring and GH-secretagogue-class AE awareness. Monitoring: DEXA at 3 and 6 months on stack; IGF-1 quarterly. Pattern Z anchor 5 (off-label / extrapolation transparency): counseling beat states explicitly that CJC-1295 and Ipamorelin are not FDA-approved for this indication; cagrilintide-monotherapy is also not FDA-approved-for-marketing-claims; the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data.

Scenario C — ad-hoc cagrilintide + semaglutide combination (contraindicated; routed to CagriSema combo). A patient seeking dual-mechanism amylin + GLP-1R approach inquires about combining cagrilintide-monotherapy with semaglutide (Wegovy 2.4 mg) as separate injections. Counseling beat: this ad-hoc combination is mechanistically duplicative of CagriSema; the CagriSema combo product (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose co-formulated; REDEFINE-1 combo arm approximately 22.7% effect; NDA filed per Novo Nordisk public disclosures; cross-reference [[CagriSema Protocol]]) is the dose-controlled co-formulation evidence-base-anchored option. The ad-hoc combination is research-state-uncharacterized for safety / efficacy / pharmacokinetic-interaction relative to CagriSema’s controlled co-formulation; the patient should be on CagriSema combo rather than ad-hoc combination.

Pattern W cross-check at §9.5. Each combination above is reconciled with §2 (no patient enters a combination with a §2.4 conservative-application contraindicated agent), §6 (combination AE-management does not mask or substitute for individual-agent AE-management algorithms), and §10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

---

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the protocol’s patient-counseling content — the conversations the clinician has with the patient at each protocol phase. §10 is the operational anchor for Pattern Z (cumulative-tone calibration) and for Pattern R (lead-framing calibration); the counseling beats are the most reader-facing content the protocol produces and are most vulnerable to drift from “presenting facts” to “steering decisions.”

The five Pattern Z calibration anchors are verbatim examples from semaglutide v1.0-final, established as the calibration baseline post-iteration-4 verification on 2026-05-11; canonical source is /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md. The five anchors as applied to cagrilintide-monotherapy:

• Anchor 1 — Lead with what the option IS. The cagrilintide-monotherapy option leads with what it IS (long-acting amylin receptor agonist; Phase 2 + REDEFINE-1 cagrilintide-alone arm evidence base; mechanism-class-distinct from GLP-1R / GIP / glucagon classes).
• Anchor 2 — Compounded vs FDA-approved patient-counseling beat — adapted to pre-FDA-approval-for-marketing-claims state. Cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; the 503A / 503B post-FDA-approval shortage-period framework does not apply; the compounded-cagrilintide framing is structurally adapted (§10.3 develops, parallel to Retatrutide protocol §10.3 + canonical Cagrilintide §8.3.2).
• Anchor 3 — Pregnancy section research-state-leading structure. LEADS with Parker 2025 GLP-1 RA pooled regulatory pregnancy data (PMID 40329607) + acknowledgment of cagrilintide-specific data absence + pramlintide adjacent-class reference. PK arithmetic + class-level conservative-application contraindication framing AFTER the research-state lead (§10.4 develops; verbatim canonical anchor 3 structure adapted to the cagrilintide-specific pregnancy-data-absence state).
• Anchor 4 — Multi-dimensional comparator framing. Cagrilintide-monotherapy vs CagriSema combo vs FDA-approved class comparators (semaglutide, tirzepatide) with 8+ comparator dimensions (§10.5 develops).
• Anchor 5 — Off-label / extrapolation transparency — DOMINANT subsection for cagrilintide-monotherapy. Cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; current clinical use is via compounded preparations, investigational supply, or CagriSema combo (the prioritized current-access pathway). The Anchor 5 framing — present trial-population scope as fact; frame extrapolation as research-state-paused, NOT as bias-vocabulary deficit framing; explicit off-label labeling; informed-consent acknowledgement; close with shared-decision-making — is the dominant calibration surface for cagrilintide-monotherapy (§10.6 develops).

Compound-specific counseling beats MUST verify against verbatim canonical anchors, not just abstract principles. §10 production includes a verbatim-diff check against the canonical anchor file at PSV iteration 1.

10.2 Initiation conversation (§4 anchor)

The initiation conversation occurs at pre-treatment workup completion / §4 initiation visit. Required counseling beats:

• What cagrilintide-monotherapy IS (Anchor 1): long-acting amylin receptor agonist; mechanism-class-distinct from GLP-1R / GIP / glucagon classes; Phase 2 + REDEFINE-1 cagrilintide-alone arm evidence base; current regulatory state is investigational-pre-FDA-approval-for-marketing-claims with monotherapy development paused (Pattern Z.research-precision framing — paused, not abandoned).
• What it does for the patient’s indication (Anchor 1, Anchor 4): expected effect-size approximately 11.8% body weight loss at 68 weeks per REDEFINE-1 cagrilintide-alone arm at 2.4 mg weekly maintenance; comparator framing across cagrilintide-monotherapy / CagriSema combo / semaglutide / tirzepatide.
• The 16-week titration schedule (§4): standard pace 0.3 → 0.6 → 1.2 → 1.7 → 2.4 mg over 16 weeks; slow-titration option doubled-interval; adjustable to patient tolerability.
• The AE profile expected at each titration step (§6 GI class): nausea anticipated, typically attenuates, management strategies non-pharmacologic first + ondansetron PRN second; reassurance that AE-emergence is anticipated.
• The cagrilintide-specific bone-biology surveillance (§3.7 + §6.10): mechanism-class research direction; baseline DXA per age- and risk-stratified guidelines; periodic re-assessment per §5.3.
• The pre-conception planning beat for reproductive-age patients (Anchor 3): pharmacokinetic washout arithmetic; approximately 60-day conservative-application pre-conception window; post-discontinuation weight-regain trajectory (class-comparator GLP-1 RA literature; cagrilintide-monotherapy-specific data research-state-incomplete).
• Access-pathway realities (Anchor 2 + Anchor 5): current-access pathways are CagriSema combo (anticipated FDA approval pending; the prioritized current pathway; cross-reference [[CagriSema Protocol]]), compounded cagrilintide (§10.3 framing), or clinician-judgment investigational supply (§10.6 framing); cost / access realities vary.
• What the patient signals back if any concern emerges (escalation pathway): symptoms warranting in-person evaluation within 48 hours (severe persistent abdominal pain, vomiting blood, signs of severe AE, new low-trauma fracture).

10.3 Compounded-cagrilintide counseling — Anchor 1 + Anchor 2 cagrilintide-specific calibration (pre-FDA-approval state)

Cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; the canonical Anchor 1 framing (compounded option IS a real-world clinical option used by substantial patient population through 503A / 503B regulatory pathways) and the canonical Anchor 2 framing (compounded vs FDA-approved comparison) are structurally adapted for the pre-approval state — structurally parallel to the Retatrutide protocol §10.3 calibration.

What compounded cagrilintide IS in the pre-FDA-approval state (factual research-state observation framing; Pattern Z compliant — leads with what compounded cagrilintide IS, not with what it isn’t):

Compounded cagrilintide is a real-world phenomenon in the research-chemical and gray-market peptide-vendor channels. It is used by patients who (a) are following the CagriSema combo regulatory readout schedule and want early access to the amylin-mechanism component ahead of FDA approval; (b) have specific mechanism-class preference for amylin receptor agonism alone (without the GLP-1R component); (c) have prior GLP-1 RA non-response or intolerance and are seeking the amylin-mechanism alternative; (d) participate in research-direction-tracking or peptide-research-community contexts where the early-access pathway through compounded sourcing is normalized.

Specific operational differences from the FDA-approved-formulation compounded landscape (factual scope, not deficit framing):

• No FDA-declared shortage status applies because cagrilintide-monotherapy has no FDA-approved indication to be in shortage of. The 503A (state-licensed pharmacy compounding) and 503B (FDA-registered outsourcing facility compounding) regulatory pathways that operate under shortage preconditions do not apply. Operational implication: the regulatory frame patients may be familiar with from compounded semaglutide / tirzepatide during the 2022-2024 shortage periods does not apply to compounded cagrilintide.
• Sourcing-channel landscape differs. Compounded cagrilintide sources from research-chemical vendors and international-sourcing channels — quality, purity, identity, and counterion-form variability is structurally greater than 503A/503B post-FDA-approval-shortage compounding. Operational implication: per-batch certificate of analysis review, sterility testing per USP standards where applicable, and sourcing-vendor reputation evaluation are more variable.
• Patient-population scope is structurally smaller than the compounded semaglutide / tirzepatide patient populations.
• No FDA-approved-sponsor-formulation comparator exists at the time of clinician-patient discussion — patients cannot compare compounded cagrilintide quality against an FDA-approved Novo Nordisk cagrilintide-monotherapy product (which does not exist as of 2026-05-13, given the monotherapy-paused state); they can only compare against research-grade reference material and other compounded cagrilintide sources. The pramlintide FDA-approved-amylin-analog (Symlin; AstraZeneca) is the closest within-amylin-class FDA-approved reference but structurally different (non-acylated, TID, insulin-adjunct indication).

Pattern Z compliant patient-counseling beat for the compounded-cagrilintide question:

“Compounded cagrilintide as it exists in research-chemical and international-sourcing channels is a real phenomenon — patients seeking it typically have specific reasons (anticipated FDA approval timing for the CagriSema combo product, mechanism-class preference for amylin alone, prior GLP-1 RA non-response or intolerance, or interest in the published cagrilintide-monotherapy evidence base). The operational landscape is structurally different from the compounded semaglutide / tirzepatide context that emerged during the 2022-2024 shortages, because there is no FDA-approved cagrilintide-monotherapy product for compounding pharmacies to compound from under shortage status. The sourcing is from research-chemical vendors and international-sourcing channels, and the quality variability is structurally greater than 503A/503B compounding. Notably, the prioritized current-access pathway for cagrilintide-component clinical use is the CagriSema combo product (cagrilintide + semaglutide; NDA filed; FDA approval pending) — that’s the pathway with the dose-controlled co-formulation and the evidence-base-anchored 22.7% combo-arm effect from REDEFINE-1. If you’re specifically interested in cagrilintide alone and considering the compounded route, let’s review the specific sourcing vendor’s quality practices — certificate of analysis if available, vendor reputation, reconstitution and storage discipline — and walk through what we know and don’t know about the formulation. That’s how the decision gets made well in this pre-approval context.”

What Pattern Z compliance does NOT mean. It does not mean presenting compounded cagrilintide as equivalent to investigational-supply cagrilintide in every dimension; it does not mean presenting CagriSema combo as exclusively legitimate. It means presenting the options factually with their respective trade-offs, allowing the patient and clinician to make a choice anchored to the patient’s circumstances (access, mechanism-class preference, sourcing-vendor quality evaluation, regulatory-status comfort, CagriSema combo vs cagrilintide-monotherapy preference).

10.4 Pregnancy-planning conversation (Anchor 3 — LEADS with human research-state data)

For reproductive-age patients on cagrilintide-monotherapy. The conversation LEADS with human pregnancy-exposure research-state data, not with PK arithmetic or class-level contraindication framing. Adapted to the cagrilintide-specific pregnancy-data-absence state.

Required counseling beats:

• Human pregnancy-exposure data — Parker SE et al. 2025 (PMID 40329607). Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, and class-related compounds). Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete; authors call for prospective pregnancy registries. Cagrilintide-specific or amylin-class pregnancy-exposure data is not included in the Parker 2025 dataset; cagrilintide-specific trial-program unplanned-pregnancy exposure data emerges through primary publication and regulatory submission reporting of the Phase 2 and REDEFINE-1 cagrilintide-alone arm. Pramlintide adjacent-class pregnancy data is the within-amylin-class reference (Category C; insufficient human data per FDA labeling; not a Category-X-equivalent contraindication).

• Pharmacokinetic facts (post-research-state-lead). Cagrilintide elimination half-life approximately 7 days; approximately 5 half-lives (approximately 35 days) for >95% pharmacokinetic clearance. With conservative pharmacodynamic margin, approximately 60-day pre-conception discontinuation window.

• Standard practice framing. Discontinuation upon pregnancy awareness for cagrilintide-monotherapy users; class-level conservative-application of GLP-1 RA pregnancy-discontinuation framing per §2.4.

• Animal data context. Class-level conservative application. Cagrilintide-specific human pregnancy-exposure data is research-state-incomplete; the adjacent GLP-1 RA class human pooled data (Parker 2025) is the closest reference; the pramlintide adjacent-amylin-class FDA labeling does not include a Category-X-equivalent contraindication.

• Post-discontinuation weight-regain trajectory. Class-comparator GLP-1 RA evidence base (STEP-4 PMID 33755728 trajectory); cagrilintide-monotherapy-specific evidence research-state-incomplete.

• The patient’s reproductive-planning decision is patient-anchored. Some patients on protocol will plan conception within the next 1-2 years; some within the next decade; some are not planning conception at all but want awareness of the discontinuation arithmetic in case planning changes. The counseling beat presents the facts; the timing decision is patient-anchored.

• Re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per §8.6 if indication and selection criteria are met and pending cagrilintide-monotherapy or CagriSema combo regulatory status at time of consideration.

Pattern Z anchor 3 compliance verification. This counseling beat LEADS with Parker 2025 human research-state data + acknowledgment of cagrilintide-specific data absence + pramlintide adjacent-class reference. PK facts, class-level conservative-application contraindication framing, and post-discontinuation weight-regain trajectory appear AFTER the research-state lead, scoped as factual context. The patient’s decision is patient-anchored.

10.5 Comparator conversation (Anchor 4 — multi-dimensional fact presentation)

For patients with within-class and cross-class alternatives. Canonical Anchor 4 requires multi-dimensional fact presentation across 8+ dimensions — single-dimension comparison (weight magnitude alone) is the canonical pre-patch anti-anchor.

Pattern AA-precise comparator framing. Effect-size data with epistemic-status framing:

Compound	Trial / readout	Effect	Dose / duration	Epistemic status
Cagrilintide-monotherapy	REDEFINE-1 cagrilintide-alone arm (Garvey 2025 NEJM PMID 40544433; n≈853 of n=3,417)	~11.8%	2.4 mg / 68 weeks	peer-reviewed; cagrilintide-monotherapy pre-FDA-approval-for-marketing-claims; monotherapy development paused
Cagrilintide-monotherapy	Phase 2 dose-finding (Lau 2021 Lancet PMID 34798060; n=706)	~9.7% at 2.4 mg; ~10.8% at 4.5 mg	weekly / 26 weeks	peer-reviewed
CagriSema combo (cagrilintide + semaglutide)	REDEFINE-1 combo arm (PMID 40544433)	~22.7% adherent / ~20.4% treatment-policy	2.4 mg + 2.4 mg / 68 weeks	peer-reviewed; CagriSema NDA filed; FDA approval pending
Semaglutide (Wegovy)	STEP-1 (Wilding 2021)	−14.9%	2.4 mg / 68 weeks	peer-reviewed; FDA-approved for CWM
Tirzepatide (Zepbound)	SURMOUNT-1 (Jastreboff 2022)	−22.5%	15 mg / 72 weeks	peer-reviewed; FDA-approved for CWM
Tirzepatide vs semaglutide head-to-head	SURMOUNT-5 (Aronne 2025 NEJM PMID 40353578; n=751)	tirzepatide −20.2% vs semaglutide −13.7%	week 72	peer-reviewed
Pramlintide (Symlin)	12-month obesity trial (Smith 2008 PMID 18753666; n=411)	~6-8 kg sustained	TID / 12 months	peer-reviewed; FDA-approved-for-marketing-claims for T1D / T2D insulin adjunct (not weight-management indication)

Required multi-dimensional counseling beats:

• Weight-loss magnitude (Pattern V trial-anchored). Cagrilintide-monotherapy approximately 11.8% at 68 weeks (REDEFINE-1 cagrilintide-alone arm); CagriSema combo approximately 22.7% at 68 weeks (REDEFINE-1 combo arm); semaglutide approximately 14.9% (STEP-1) or up to 18.7% (STEP-UP 7.2 mg dose); tirzepatide approximately 22.5% (SURMOUNT-1 15 mg) or 20.2% at week 72 head-to-head (SURMOUNT-5). Pramlintide approved-use weight effect is substantially smaller (different indication, different design generation).

• Regulatory status (Pattern AA precision). Cagrilintide-monotherapy is NOT FDA-approved-for-marketing-claims as of 2026-05-13; monotherapy development is paused; cagrilintide is progressed primarily as the CagriSema combo component. CagriSema is anticipated-FDA-approval with NDA filed per Novo Nordisk public disclosures. Semaglutide is FDA-approved (Wegovy CWM, Ozempic T2D + CV risk + CKD-in-T2D label expansion 2025, ESSENCE MASH F2/F3 label expansion 2025). Tirzepatide is FDA-approved (Mounjaro T2D, Zepbound CWM). Pramlintide is FDA-approved-for-marketing-claims for T1D / T2D insulin-adjunct indication (Symlin; AstraZeneca; FDA approved 2005).

• Mechanism-class differentiation. Cagrilintide = amylin receptor agonist (calcitonin-receptor-heterodimer; brainstem AP/NTS dominant); semaglutide / liraglutide = GLP-1R agonist (hypothalamic + hindbrain + vagal-afferent); tirzepatide = GLP-1/GIP dual incretin; pramlintide = amylin receptor agonist (non-acylated, short-acting; first-generation amylin analog). The non-overlapping satiety pathways (amylin + GLP-1) are the pharmacological foundation for the CagriSema combo additive weight-loss effect.

• Cardiovascular outcomes evidence base. Cagrilintide-monotherapy: research-state-incomplete (no standalone CVOT). CagriSema: REDEFINE-3 CVOT RECRUITING — [[CagriSema Protocol]]. Semaglutide: SELECT MACE HR 0.80 in obesity + CVD (Lincoff 2023 PMID 37952131) — FDA-approved CV-risk indication 2024. Tirzepatide: SURMOUNT-MMO Phase 3 active.

• MASH approval status. Cagrilintide-monotherapy: research-state-incomplete. CagriSema: combo-product MASH context [[CagriSema Protocol]]. Semaglutide: FDA-approved MASH F2/F3 per ESSENCE (PMID 40305708; 2025 label expansion). Tirzepatide: MASH program in development (SYNERGY-NASH Phase 2 PMID 38856224). Resmetirom (Madrigal): FDA-approved 2024 for non-cirrhotic F2/F3 MASH (non-GLP-1 mechanism class).

• Kidney outcomes evidence base. Cagrilintide-monotherapy: research-state-incomplete. Semaglutide: FLOW kidney composite + CV death HR 0.76 in T2D + CKD (Perkovic 2024 PMID 38785209) — FDA-approved indication 2025. Tirzepatide: kidney outcomes in development.

• Ophthalmologic class-differentiation (NAION). Class-context: NAION signal documented for semaglutide (Hathaway 2024 PMID 38958939); signal absent for tirzepatide at same analytic threshold (Lakhani 2025 PMID 40383360). Cagrilintide-monotherapy NAION-signal characterization is research-state-incomplete; the amylin-mechanism class is mechanism-class-distinct from the GLP-1R class, so the GLP-1R-class NAION signal does not directly translate to the amylin-mechanism class. Pattern AA precision: NAION is class-context post-marketing signal under research-state-active evaluation; not a labeled warning.

• Bone-biology surveillance (cagrilintide-mechanism-class-specific per §6.10). Cagrilintide-mechanism-class-anchored research direction (calcitonin-receptor-heterodimer architecture). The GLP-1R / GIP / glucagon mechanism classes do not carry this mechanism-class research direction; clinician-judgment conservative-application is cagrilintide-monotherapy-specific. Pramlintide adjacent-class 2005-onward post-marketing experience supports the absence of a major bone-biology signal at the within-amylin-class level.

• Hypoglycemia profile. Cagrilintide-monotherapy: favorable hypoglycemia profile (no β-cell insulin-stimulating mechanism); minimal monotherapy hypoglycemia risk. GLP-1 RA class: also favorable as monotherapy at chronic weight management dose; hypoglycemia emerges in concurrent insulin / SU use. Tirzepatide: similar GLP-1R-mediated favorable profile.

• GI tolerability profile. All within-class-typical GI-dominant AE profile; titration discipline similar across cagrilintide / GLP-1 RAs / tirzepatide.

• Route / platform availability. Cagrilintide: SC injection only (Phase 2 / Phase 3 trial-program supply and compounded preparations); no oral cagrilintide formulation in publicly disclosed pipeline. Semaglutide: SC injection (Wegovy/Ozempic) + oral (Rybelsus 25 mg approved 2025). Tirzepatide: SC injection (Zepbound/Mounjaro) only as of 2026-05-13. CagriSema: SC injection co-formulation (single-injection cagrilintide + semaglutide).

• Cost and access. Cagrilintide-monotherapy: compounded-preparation cost varies by sourcing vendor; no FDA-approved-product list price exists. CagriSema: anticipated FDA-approved-product list price per Novo Nordisk pricing decisions post-approval. Semaglutide / tirzepatide: FDA-approved-product list prices vary by indication and jurisdiction; insurance-coverage realities for CWM indications are more variable than for T2D indications. Pramlintide: FDA-approved-product list price for T1D / T2D insulin-adjunct indication.

Patient-counseling beat (verbatim canonical Anchor 4 framing — affirms multiple compounds; acknowledges advantages explicitly; closes with shared-decision-making):

“Cagrilintide-monotherapy, CagriSema combo, semaglutide, tirzepatide, and pramlintide are all amylin / incretin pathway weight-management or insulin-adjunct options at different stages of development, approval, and clinical use. Cagrilintide-monotherapy is investigational with monotherapy development paused — the cagrilintide-alone arm of REDEFINE-1 showed approximately 11.8% body weight loss at 68 weeks; the same trial’s CagriSema combo arm showed approximately 22.7%. CagriSema is the prioritized current pathway for cagrilintide-component clinical use — NDA filed; FDA approval pending. Semaglutide and tirzepatide are FDA-approved with established evidence bases — semaglutide adds cardiovascular, kidney, and MASH approvals; tirzepatide shows the largest single-compound weight-loss magnitude (approximately 22.5% in SURMOUNT-1; 20.2% in SURMOUNT-5 head-to-head). Pramlintide is FDA-approved as an insulin-adjunct for T1D / T2D but uses a different design generation. The compounds differ on weight magnitude, mechanism class (amylin vs GLP-1R vs GLP-1/GIP), regulatory status, evidence-base maturity, cardiovascular / kidney / MASH outcomes evidence, NAION class-differentiation, bone-biology mechanism-class research direction (cagrilintide-specific), GI tolerability profiles, access pathways, cost. Here are the facts on each dimension; let’s discuss which factors matter most for your situation.”

10.6 Off-label / extrapolation conversation (Anchor 5 — DOMINANT subsection for cagrilintide-monotherapy)

This is the dominant Pattern Z calibration subsection for cagrilintide-monotherapy as of 2026-05-13. Because cagrilintide-monotherapy is not FDA-approved-for-marketing-claims and monotherapy development is paused, every clinical use of cagrilintide-monotherapy today is some form of (a) historical trial-enrollment closure (REDEFINE-1 cagrilintide-alone arm COMPLETED; Phase 2 dose-finding COMPLETED), (b) clinician-judgment off-label use of compounded preparations from research-chemical / international-sourcing channels (§10.3 framing), or (c) clinician-judgment off-label investigational use where regulatory pathway supports it. The Anchor 5 framing — present trial-population scope as fact; frame extrapolation as research-state-paused (NOT bias-vocabulary deficit framing); explicit off-label labeling; informed-consent acknowledgement; close with shared-decision-making — is the dominant calibration surface.

Pattern Z.research-precision discipline at §10.6. The cagrilintide-monotherapy development status is described as paused / progressed primarily as combo / monotherapy Phase 3 not advanced — factual research-state framing. The protocol does NOT use abandoned / failed / shelved / highly experimental / fringe vocabulary. The cagrilintide-monotherapy track is real, the evidence base is peer-reviewed (Phase 2 Lau 2021 PMID 34798060 + Phase 3 cagrilintide-alone arm of REDEFINE-1 Garvey 2025 PMID 40544433), and the pause is a Novo Nordisk commercial-strategy decision documented in the company’s public pipeline disclosures.

Required counseling beats for cagrilintide-monotherapy off-label / extrapolation conversation:

(a) CagriSema combo pathway counseling (the prioritized current-access pathway). CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose co-formulated) is the prioritized current-access pathway for cagrilintide-component clinical use. NDA filed with FDA per Novo Nordisk public disclosures; FDA approval pending. Patient and clinician evaluate CagriSema as the within-amylin-mechanism + within-GLP-1R-mechanism combo product — cross-reference [[CagriSema Protocol]] for combo-product pre-treatment workup, initiation, maintenance, AE management, combination rules, and counseling. Patient understands: CagriSema is the regulatory-state-prioritized pathway for combined amylin + GLP-1 effect; cagrilintide-monotherapy as a separate option exists only at clinician-judgment off-label / pre-FDA-approval-for-marketing-claims level.

(b) Off-label use of compounded cagrilintide-monotherapy (per §10.3 framing). Patient understands: cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; monotherapy development is paused; clinical use is off-label / pre-approval; compounded cagrilintide sources from research-chemical / international-sourcing channels with structural quality variability greater than 503A/503B post-FDA-approval-shortage compounding; the trial-population evidence base supports the 2.4 mg weekly maintenance dose per Phase 2 + REDEFINE-1 cagrilintide-alone arm; informed-consent acknowledgement at the regulatory-state, sourcing-channel-quality, and off-label-use layers.

(c) Off-label use of investigational supply (where research-protocol acquisition pathway exists; rare given the monotherapy-paused state). Patient understands: cagrilintide-monotherapy is not FDA-approved-for-marketing-claims; investigational-supply acquisition pathways are not publicly enumerated by Novo Nordisk for cagrilintide-monotherapy as of 2026-05-13; the prioritized Novo Nordisk pathway is CagriSema combo. Investigational-supply use is at clinician-judgment within informed-consent and primary-source-supported clinical reasoning.

(d) Microdosing / off-label-dose-range extrapolation. Pattern Z anchor 5 framing: the Phase 2/3 trial-population evidence base supports the trial-protocol-defined 2.4 mg weekly maintenance dose; microdosing or off-label-dose-range extrapolation beyond the trial-protocol range is research-state-novel — the effects at sub-trial doses are research-state-uncharacterized. The known AE profile (GI dominant per §6.2; gallbladder per §6.3; pancreatitis class-level per §6.4; bone-biology mechanism-class-specific per §6.10; pregnancy class-level per §6.9) applies whether the patient is in the studied population or not.

(e) Extrapolation beyond trial-enrolled phenotype (e.g., cagrilintide-monotherapy use in T2D-positive obesity where Phase 2 / REDEFINE-1 cagrilintide-alone arm excluded T2D; cagrilintide-monotherapy use in pediatric / adolescent population where no Phase 3 trial exists; cagrilintide-monotherapy use in pregnancy / lactation contexts class-level conservative-application contraindicated). Pattern Z anchor 5 framing applies: trial-population scope as fact; extrapolation as research-state-incompleteness; informed-consent acknowledgement; shared-decision-making.

Patient-counseling beat (verbatim canonical Anchor 5 framing — adapted for cagrilintide-monotherapy pre-FDA-approval-for-marketing-claims state with Pattern Z.research-precision applied):

“Cagrilintide-monotherapy is investigational with monotherapy development paused — Novo Nordisk has progressed the compound primarily as the CagriSema combo component (cagrilintide + semaglutide; NDA filed; FDA approval pending) rather than as a standalone NDA submission. The published evidence base for cagrilintide-monotherapy is real: Phase 2 dose-finding (Lau 2021 Lancet) and Phase 3 cagrilintide-alone arm of REDEFINE-1 (Garvey 2025 NEJM) showing approximately 11.8% body weight loss at 68 weeks at 2.4 mg weekly. Current clinical access to cagrilintide-monotherapy is via compounded preparations from research-chemical / international-sourcing channels (with the pre-FDA-approval-compounding structural variability we discussed) or via clinician-judgment investigational pathways. The prioritized current pathway for combined cagrilintide-mechanism clinical use is the CagriSema combo product — that’s the regulatory-state-anchored route with the dose-controlled co-formulation and the higher-magnitude approximately 22.7% combo effect from REDEFINE-1. Use of cagrilintide-monotherapy outside the trial-population — different dose ranges, different phenotype, different indication — is research-state-incomplete; we don’t have Phase 3 evidence for those uses. The known side-effect profile is GI dominant, with class-level gallbladder and pancreatitis considerations, with cagrilintide-mechanism-class-specific bone-biology surveillance per the calcitonin-receptor-heterodimer architecture. Let’s discuss what you’re hoping to achieve, what the evidence does and doesn’t tell us about your specific situation, what monitoring would matter if you decided to proceed, and which access pathway is workable for your circumstances — including whether the CagriSema combo product matches your clinical objective.”

10.7 Discontinuation conversation (§8 anchor)

For patient-preference, AE-driven, pre-conception, access-barrier, or alternative-pathway-transition discontinuation. Required counseling beats:

• Reason for discontinuation framing. Patient-preference (legitimate); AE-attribution per §6 framework; pre-conception planning per §8.4 arithmetic + Anchor 3 framing per §10.4; access-barrier (e.g., compounded supply closure per §8.7 Scenario F); alternative-pathway-transition (e.g., transition to CagriSema combo per [[CagriSema Protocol]] or to FDA-approved class comparators per §10.5).
• Taper schedule (per §8.3): 2.4 mg → 1.7 mg × 4 weeks → 1.2 mg × 4 weeks → 0.6 mg × 4 weeks → off. Clinician-judgment within published-trial-program reference; not FDA-labeled.
• Post-discontinuation weight-regain framing (per §8.5): class-comparator GLP-1 RA STEP-4 trajectory; cagrilintide-monotherapy-specific evidence research-state-incomplete. Not pathologized; framed as expected biological response.
• Re-initiation or transition pathway (per §8.6): re-initiation via §4 starting dose if cagrilintide-monotherapy continued; transition to CagriSema combo via [[CagriSema Protocol]] §4 if combo-pathway selected; transition to FDA-approved class comparators if cross-class selected.

10.8 Pattern Z self-audit on §10 counseling beats

The five Anchors + cagrilintide-specific calibration are the self-audit checklist for this protocol’s §10 counseling-beat language. A Pattern Z violation in cagrilintide-protocol §10 is positive if any of the following appear:

• Cagrilintide-monotherapy development described with bias-vocabulary (“abandoned” / “failed” / “shelved” / “highly experimental” / “fringe” / “discontinued”) rather than research-state-precision (“paused” / “progressed primarily as combo” / “monotherapy Phase 3 not advanced”) — violates Pattern Z.research-precision per AC2-26 System Observations 2026-05-13.
• Compounded cagrilintide framed as default-suspect or as steered-against — violates §10.3 retatrutide-parallel pre-approval Anchors 1+2 calibration.
• Pregnancy-planning framed with PK arithmetic LEADING and human research-state data SECONDARY — violates Anchor 3 LEAD discipline.
• Comparator framing using “best in class,” “next generation,” “leading amylin compound” without trial-anchored multi-dimensional fact presentation — violates Pattern AA precision + Anchor 4 multi-dimensional discipline.
• Off-label use framed as if labeled — violates Anchor 5 explicit-off-label-framing discipline.
• Single-mechanism-direction extrapolation framing (e.g., “Cagrilintide will work better than semaglutide because amylin > GLP-1”) — extrapolates mechanism-class differentiation beyond research-state evidence; violates Pattern V direction-of-effect.
• CagriSema combo pathway framed without explicit Pattern AA regulatory-state precision (NDA filed; FDA approval pending) — violates Pattern AA.marketing-claims discipline.
• Cagrilintide-specific bone-biology surveillance framed as established signal rather than mechanism-class-anchored research direction — violates Pattern Z.research-precision; violates Pattern V (signal direction-of-effect requires established evidence).

The §10 production agent runs the eight-violation self-audit before handoff to the verification cycle.

---

11. Source citations

11.1 Purpose

Define the bibliography format, evidence-hierarchy tiers, and identifier-integrity discipline (Pattern AB.1 / AB.2 / AB.4) for this protocol. Every effect-size claim, dose threshold, contraindication framing, and counseling-beat fact-anchor traces to a §11 citation entry. Pattern AB standing scans operate at this section. Cagrilintide-specific Bibliography: cross-reference /Process/Cagrilintide/Cagrilintide - Bibliography.md for the full v1.0-final cagrilintide canonical Bibliography (Phase 2 ~22 unique PMIDs + 7 ClinicalTrials.gov v2 API trial records); the §11.5 subset below reflects the load-bearing primary-source anchors for this protocol.

11.2 Bibliography format

Each citation entry contains: First author last name, et al.; Title (exact); Journal, Year, Volume, Pages; PMID; DOI (if available); NCT (for trial reports); Effect-size summary (one-line load-bearing fact); Citation context (which protocol sections cite this source).

11.3 Evidence hierarchy tiers

• Tier 1 — pivotal Phase 3 RCT with FDA-label-supporting or registration-supporting trial-program inclusion. For cagrilintide-monotherapy: REDEFINE-1 cagrilintide-alone arm (PMID 40544433) is the load-bearing Tier 1 anchor. Pattern AA.marketing-claims precision: REDEFINE-1 is a CagriSema combo registration Phase 3 with cagrilintide-alone arm as a four-arm-design reference; the cagrilintide-alone arm data is peer-reviewed and Tier 1 for cagrilintide-monotherapy claims.
• Tier 1.5 — Phase 3 head-to-head RCT comparing within-class or cross-class alternatives. For cagrilintide-monotherapy: SURMOUNT-5 (tirzepatide vs semaglutide PMID 40353578) is the closest within-Module-5 head-to-head reference (cross-class to cagrilintide).
• Tier 2 — Phase 2 RCT, large Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper. For cagrilintide-monotherapy: Phase 2 dose-finding (Lau 2021 PMID 34798060) is the load-bearing Tier 2 dose-finding anchor; Phase 1b combination (Enebo 2021 PMID 33894838) provides exploratory cagrilintide-alone reference data; Phase 1 PK studies (Andreasen 2020 PMID 32852869; Vrhovac Madunić 2022 PMID 35156012) anchor pharmacokinetics.
• Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series. For cagrilintide-monotherapy: cagrilintide-specific post-marketing data does not exist (pre-FDA-approval state); pramlintide adjacent-class 2005-onward post-marketing experience is the closest within-amylin-class Tier 3 reference (no major MTC, pancreatic cancer, or bone-biology signal at the pramlintide post-marketing scale).

11.4 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4

Pattern AB requires every PMID, NCT, and DOI to be verified by content, not by existence. PMID verified by retrieving abstract and matching abstract title, authors, journal, year, trial-name / intervention to citation entry. NCT verified by retrieving ClinicalTrials.gov entry and matching sponsor, intervention, indication, phase, status to citation entry. DOI verified by resolving to publisher page. Pattern AB.4 cascade scan when any identifier is corrected — every occurrence updated in the same commit. The cagrilintide canonical Bibliography passed PSV iteration 1 with 22/22 PMIDs + 7/7 NCTs verified (per canonical v1.0-final verification chain status); this protocol’s Bibliography subset inherits the canonical’s PSV verification.

11.5 Cagrilintide-monotherapy protocol bibliography subset

Tier 1 — pivotal Phase 3 RCT, cagrilintide-alone arm.

• Garvey WT, et al. Phase 3 trial of cagrilintide and semaglutide (CagriSema) in obesity. N Engl J Med 2025;392:2065-2076. PMID 40544433. NCT05567796. REDEFINE-1; cagrilintide-alone arm load-bearing Phase 3 dataset for standalone cagrilintide; approximately 11.8% body weight loss at 68 weeks at 2.4 mg weekly maintenance in non-diabetic obesity; four-arm design (CagriSema combo, cagrilintide-alone, semaglutide-alone, placebo). Cited in §1.2, §1.5, §2.2, §4.6, §5.5, §6.1, §7.4, §10.5, §11.3, §12 decision tree.

Tier 1 — pivotal Phase 3 RCT, CagriSema combo (cross-reference to [[CagriSema Protocol]] for combo-product detail).

• Davies MJ, et al. Phase 3 trial of CagriSema in obesity and type 2 diabetes. N Engl J Med 2025;392:2077-2088. PMID 40544432. NCT05394519. REDEFINE-2; CagriSema combo registration in obesity + T2D; combo-product anchor — primarily [[CagriSema Protocol]] scope. Cited in §1.2, §10.5.

Tier 2 — Phase 2 dose-finding monotherapy.

• Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160-2172. PMID 34798060. NCT03856047. Phase 2 dose-finding cagrilintide-monotherapy; n=706; 26 weeks; six arms 0.3 / 0.6 / 1.2 / 2.4 / 4.5 mg cagrilintide weekly plus liraglutide 3.0 mg active comparator plus placebo; dose-responsive body weight reduction approximately 6.0-10.8% across cagrilintide doses; 2.4 mg arm approximately 9.7%; 2.4 mg dose selected for Phase 3 carryover. Cited in §1.2, §1.5, §2.2, §4.3, §6.1, §10.5, §11.3.

Tier 2 — Phase 1b combination study + Phase 1 PK studies.

• Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021;397:1736-1748. PMID 33894838. NCT03600480. Phase 1b combination cagrilintide + semaglutide; n=95; 20 weeks; combo arm up to 17.1% body weight loss; cagrilintide-alone exploratory reference arm. Cited in §1.2, §11.3.

• Andreasen CR, et al. Pharmacokinetics and pharmacodynamics of single-dose cagrilintide 2·4 mg in healthy individuals. Clin Pharmacokinet 2020;59:1219-1228. PMID 32852869. Phase 1 single-dose PK; cagrilintide elimination half-life approximately 7 days; dose-proportional PK. Cited in §1.1, §6.9, §8.4, §11.3.

• Vrhovac Madunić I, et al. Multiple-dose pharmacokinetics, pharmacodynamics, safety, and tolerability of cagrilintide. Clin Pharmacokinet 2022;61:489-501. PMID 35156012. Phase 1 multiple-dose PK; steady-state characteristics supporting weekly dosing. Cited in §1.1, §11.3.

Tier 2 — mechanism and engineering primary literature.

• Lau J, et al. Discovery of cagrilintide (NN9838 / AM833), a long-acting amylin analog with a fatty-acid moiety. J Med Chem 2021. PMID 34288673. Engineering and discovery publication; C18 fatty-diacid acylation; anti-fibrillation amino-acid substitutions; medicinal-chemistry candidate-selection. Cited in §1.1.

• Larsen AT, et al. Differential signaling at AMY1 vs AMY3 receptor subtypes and cagrilintide-mediated weight loss attribution. Cell Metab 2023. PMID 36584289. Brain AMY1/AMY3 mechanism work; clinical translation research direction. Cited in §1.1.

Tier 1.5 — head-to-head Phase 3 RCT cross-class reference.

• Aronne LJ, et al. Tirzepatide vs Semaglutide for Weight Management in Adults with Obesity. N Engl J Med 2025. PMID 40353578. NCT05822830. SURMOUNT-5; n=751; tirzepatide −20.2% vs semaglutide −13.7% at week 72; head-to-head within-class anchor for §10.5 comparator framing. Cited in §10.5.

Tier 1 — class-comparator reference for §10.5 comparator framing.

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. PMID 33567185. NCT03548935. STEP-1; semaglutide approximately 14.9% at 68 weeks; FDA-approved CWM Wegovy 2.4 mg. Cited in §10.5.

• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216. PMID 35658024. NCT04184622. SURMOUNT-1; tirzepatide approximately 22.5% at 15 mg; FDA-approved CWM Zepbound. Cited in §7.5, §10.5.

• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232. PMID 37952131. NCT03574597. SELECT; semaglutide CV risk reduction in non-diabetic obesity + CVD; HR 0.80 MACE. Cited in §10.5.

• Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121. PMID 38785209. NCT03819153. FLOW; semaglutide CKD-in-T2D kidney composite + CV death HR 0.76. Cited in §10.5.

• Sanyal AJ, Newsome PN, et al. Phase 3 trial of semaglutide in MASH. N Engl J Med 2025;392:2089-2099. PMID 40305708. NCT04822181. ESSENCE; semaglutide FDA-approved MASH F2/F3 2025. Cited in §10.5.

• Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: STEP 4. JAMA 2021;325:1414-1425. PMID 33755728. NCT03548987. STEP-4; class-comparator post-discontinuation weight-regain trajectory; cited in §6.9, §8.5, §10.4.

Tier 1 / Tier 2 — pregnancy and AE-class reference.

• Parker SE, et al. Maternal Pregnancy Exposure to GLP-1 Receptor Agonists: A Pooled Analysis. Diabetes Obes Metab 2025;27:2940-2952. PMID 40329607. Parker 2025 pooled GLP-1 RA regulatory pregnancy data; cagrilintide-specific data NOT included; class-context human pregnancy-exposure reference. Cited in §6.9, §10.4.

• Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 2024;142:732-739. PMID 38958939. NAION class-context post-marketing signal for semaglutide. Cited in §6.5, §10.5.

• Lakhani M, Kwan ATH, et al. Tirzepatide and the absence of NAION class-context signal. Am J Ophthalmol 2025. PMID 40383360. NAION class-differentiation; tirzepatide signal-absent at Lakhani 2025 analytic threshold. Cited in §6.5, §10.5.

Tier 1 — within-amylin-class adjacent reference (pramlintide).

• Smith SR, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008;31:1816-1823. PMID 18753666. Pramlintide obesity 12-month trial; n=411; approximately 6-8 kg sustained weight loss. Pramlintide-adjacent-class reference for §10.5 comparator framing. Cited in §10.5.

• Singh-Franco D, et al. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:169-180. PMID 21199269. Pramlintide T1D / T2D meta-analysis; approximately 40-60% postprandial glucose excursion reduction. Cited in §1.2, §4.4-canonical.

Tier 2 — class-comparator MASH and other contextual references.

• Loomba R, et al. Tirzepatide MASH Phase 2 trial: SYNERGY-NASH. N Engl J Med 2024. PMID 38856224. Tirzepatide MASH Phase 2 evidence. Cited in §10.5.

Tier 2 — class-level cancer evidence base for combo-product context.

• Ko HF, et al. GLP-1 receptor agonists and cancer outcomes: a systematic review. Ann Intern Med 2026. PMID 41359966. Class-level GLP-1 RA cancer outcomes systematic review covering 11 cancers + 2 conditions across certainty tiers; relevant for CagriSema combo context via semaglutide component — primarily [[CagriSema Protocol]] scope. Cited in §6.11 cross-reference.

Pattern AB.4 standing-scan applied to §11.5. Every PMID and NCT in this subset has been content-verified via the canonical Cagrilintide v1.0-final PSV iteration 1 verification chain (Phase 10.5 — 22/22 PMIDs + 7/7 NCTs verified; AB.1/AB.2/AB.4 hygiene compliance verified; no patch cycle required). NCT03856047 = Lau 2021 Phase 2 dose-finding; NCT03600480 = Enebo 2021 Phase 1b combination; NCT05567796 = REDEFINE-1; NCT05394519 = REDEFINE-2; NCT05669755 = REDEFINE-3 CV outcomes (RECRUITING; [[CagriSema Protocol]] scope); NCT05669781 = REDEFINE-4 East Asian (RECRUITING; [[CagriSema Protocol]] scope); NCT05669742 = REDEFINE adolescent (RECRUITING; [[CagriSema Protocol]] scope). The cascade-failure pattern is the failure mode this verification prevents.

---

12. Clinical decision tree

12.1 Purpose

Phenotype-guided decision tree integrating §§1-11 into a single navigable workflow reference for the cagrilintide-monotherapy clinical-judgment use scenarios. Given the monotherapy-paused state, the decision tree’s dominant decision branch routes the patient toward the CagriSema combo pathway ([[CagriSema Protocol]]) or toward FDA-approved class comparators (semaglutide, tirzepatide) for the majority of clinical scenarios; the cagrilintide-monotherapy pathway is the narrower decision branch for patients with specific mechanism-class preferences or with prior class-comparator non-response / intolerance.

12.2 High-level decision flowchart (ASCII)

                  PATIENT PRESENTS
                         |
                         v
              [§1] Indication scope
              - CWM (BMI ≥30 or ≥27 + comorbidity)?
              - T2D-positive? → CagriSema combo pathway preferred
                         |
                         v
              [§2] Selection criteria
              - Inclusion met?            --> NO  --> Out of protocol
              - Relative exclusion?       --> Clinician judgment
              - Conservative-application contraindication? --> YES --> Out
                         |
                         v (Inclusion met, no contraindication)
              [Access-pathway decision] (§10 anchor)
              - CagriSema combo (anticipated FDA approval; prioritized current pathway)
                → [[CagriSema Protocol]]
              - Cagrilintide-monotherapy compounded (§10.3 framing)
              - Cagrilintide-monotherapy investigational supply (§10.6 framing)
              - FDA-approved class comparator (sema / tirz; §10.5 framing)
                         |
                         v (Cagrilintide-monotherapy selected)
              [§3] Pre-treatment workup
              - Standard metabolic + indication-specific panels
              - Organ-baseline (thyroid, pancreas, ophthalmology)
              - Cagrilintide-specific bone-biology baseline (§3.7)
              - Body composition baseline
                         |
                         v
              [§4] Initiation
              - 0.3 mg starting dose → 16-week titration to 2.4 mg
              - Standard pace OR slow-titration
              - Early monitoring cadence Week 2 / 5-6 / 9-12 / 16-17
              - GI tolerability management
                         |
                         v (Target dose 2.4 mg attained)
              [§5] Maintenance
              - 2.4 mg weekly; quarterly Y1, biannual thereafter
              - Cagrilintide-specific bone-biology surveillance at 24 mo intervals
                         |
                         v
              [§6/7/8] Branch points
              - AE emerges? → §6 AE-class algorithm
              - Plateau / non-response? → §7 algorithm (transition to CagriSema combo prominent)
              - Discontinuation trigger? → §8 taper / framing
                         |
                         v
              [§9] Combination decisions
              - CagriSema combo as primary cagrilintide-combination vehicle
              - Cross-Module lean-mass stack (CJC-Ipamorelin M5.6)
              - Contraindicated combinations avoided
                         |
                         v
              [§10] Counseling beats
              - Pattern Z 5-anchor compliance at every conversation
              - §10.6 Anchor 5 DOMINANT (off-label / pre-FDA-approval framing)
              - Pattern Z.research-precision: paused, not abandoned
                         |
                         v
              [§11] All claims source-anchored
              - Tier 1 / 1.5 / 2 / 3 evidence hierarchy
              - Pattern AB.4 standing scan (canonical PSV iteration 1 verified)
                         |
                         v
              [Appendix A] Verification gate
              - 4-step cycle before clinician delivery

12.3 Phenotype-guided decision matrix

Phenotype dimension	Pattern	Cagrilintide-monotherapy fit	Preferred current-access pathway	Cross-class additions
Indication = CWM, non-diabetic, BMI ≥30	REDEFINE-1 cagrilintide-alone anchored	2.4 mg weekly maintenance	CagriSema combo (anticipated FDA approval; prioritized) — [[CagriSema Protocol]]	Tirzepatide SURMOUNT-1 (higher effect, FDA-approved); semaglutide STEP-1 (FDA-approved); lean-mass stack M5.6 if lean-mass concern
Indication = CWM, BMI 27-30 + comorbidity	Phase 2 / REDEFINE-1 sub-analyses	2.4 mg weekly	CagriSema combo	Tirzepatide SURMOUNT-1 sub-group; semaglutide STEP-3 IBT intensification
Indication = CWM, T2D-positive	Phase 2 + REDEFINE-1 EXCLUDED T2D	Research-state-limited at monotherapy	CagriSema combo (REDEFINE-2 anchored; primary pathway) — [[CagriSema Protocol]]	Semaglutide T2D-indication formulation (Ozempic); tirzepatide Mounjaro
Indication = CV risk + non-diabetic obesity + CVD	No standalone cagrilintide CVOT	Research-state-incomplete	Semaglutide SELECT-anchored FDA-approved 2024; CagriSema REDEFINE-3 RECRUITING	RAS blockade; statins standard-of-care
Indication = MASH F2-F3	No standalone cagrilintide MASH evidence	Research-state-incomplete	Semaglutide ESSENCE-anchored FDA-approved 2025; Resmetirom (Madrigal)	Hepatology co-management
Indication = CKD-in-T2D	No standalone cagrilintide kidney trial	Research-state-incomplete	Semaglutide FLOW-anchored FDA-approved 2025	SGLT2 inhibitor (DAPA-CKD / EMPA-KIDNEY)
Phenotype: prior GLP-1 RA intolerance	Within-class-distinct mechanism advantage	Mechanism-class consideration	Cagrilintide-monotherapy (amylin-mechanism alone, no GLP-1R) OR CagriSema combo despite prior GLP-1 RA intolerance (semaglutide tolerability re-trial)	Tirzepatide if GIPR-component novel to patient; lifestyle intensification
Phenotype: MTC / MEN-2 family hx	§2.4 conservative-application contraindication	OUT OF PROTOCOL — conservative application	Non-amylin alternative; lifestyle / surgical pathway	Pattern AA: conservative application of class-level GLP-1 RA precedent
Phenotype: pre-conception planning	§8.4 + Anchor 3 framing	60-day conservative-application washout	Same arithmetic for cagrilintide-mono and CagriSema combo (both ~7-day half-life-based amylin component; combo also requires semaglutide pre-conception window per [[CagriSema Protocol]])	Pre-pregnancy counseling pathway
Phenotype: bone-fracture-risk-elevated	§6.10 mechanism-class research direction	Clinician-judgment conservative posture	Standard age- and risk-stratified DXA; calcium + vitamin D adequacy	Cross-class alternative (sema / tirz) if elevated concern; bone-protective adjunct
Phenotype: postmenopausal F	§3.7 cagrilintide-specific baseline DXA	Baseline DXA + 24-month interval re-DXA	Same surveillance posture for CagriSema combo per [[CagriSema Protocol]]	Calcium + vitamin D; bone-health lifestyle counseling
Phenotype: lean-mass concern (older adult, athletic)	M5.6 stack consideration	Cagrilintide-monotherapy + CJC-Ipamorelin M5.6 v3	Same lean-mass-stack consideration for CagriSema combo per [[CagriSema Protocol]] §9.3	Resistance training program co-prescription
Phenotype: cost / access barrier	§10.3 framing	Compounded cagrilintide pre-FDA-approval-compounding context	CagriSema combo cost considerations per [[CagriSema Protocol]]; FDA-approved class comparator cost considerations	Insurance-pathway counseling
Phenotype: prior cagrilintide-monotherapy non-response	§7 algorithm	Out of cagrilintide-monotherapy; transition	CagriSema combo (REDEFINE-1 combo 22.7% vs cagrilintide-alone 11.8% at 68 weeks) — primary intensification	Tirzepatide; semaglutide; behavioral intensification
Phenotype: pediatric / adolescent	No cagrilintide-monotherapy pediatric trial	Out of protocol	REDEFINE adolescent NCT05669742 RECRUITING — CagriSema combo scope [[CagriSema Protocol]]	Semaglutide STEP-TEENS FDA-approved 2022 (≥12 years)

12.4 Worked example — cagrilintide-monotherapy decision tree application

The §1.5 / §2.5 / §3.9 / §4.6 / §5.5 / §6.12 patient (48-year-old female, BMI 32, postmenopausal, non-diabetic obesity, prior weight-loss-failure with phentermine-topiramate and liraglutide; no MTC / MEN-2; no pancreatitis; no significant comorbidity beyond obesity):

Decision-tree walkthrough.

Step 1 — Indication scope (§1). CWM indication; non-diabetic obesity BMI ≥30 — within the cagrilintide-monotherapy trial-enrolled phenotype per Phase 2 + REDEFINE-1 cagrilintide-alone arm.

Step 2 — Selection criteria (§2). Inclusion met; no §2.4 conservative-application hard contraindications; bone-fracture-risk-elevated phenotype (postmenopausal age 48) handled at §3.7 pre-treatment workup with baseline DXA.

Step 3 — Access-pathway decision (§10 anchor). Patient prior liraglutide intolerance (GLP-1R-mechanism-related) → patient and clinician discuss the access-pathway options:

• CagriSema combo (the prioritized current-access pathway). Reintroduces GLP-1R component (semaglutide 2.4 mg); the patient’s prior liraglutide intolerance is a tolerability consideration for the semaglutide component. Expected effect approximately 22.7% at 68 weeks (REDEFINE-1 combo arm). [[CagriSema Protocol]] scope.
• Cagrilintide-monotherapy compounded preparation (§10.3 framing). Avoids the GLP-1R component; uses the amylin-mechanism alone. Expected effect approximately 11.8% at 68 weeks (REDEFINE-1 cagrilintide-alone arm). Compounded-source quality variability per §10.3.
• FDA-approved class comparators (§10.5 framing). Tirzepatide (Zepbound 15 mg; SURMOUNT-1 approximately 22.5%; GIPR-mechanism novel to patient relative to her liraglutide exposure); semaglutide (Wegovy 2.4 mg; STEP-1 approximately 14.9%; same GLP-1R-mechanism class as her prior liraglutide intolerance).

Step 4 — Patient selects cagrilintide-monotherapy via compounded preparation (§10.3 access pathway) given her specific mechanism-class preference to avoid GLP-1R after the liraglutide intolerance. Informed-consent acknowledgement at §10.6 Anchor 5 framing (off-label / pre-FDA-approval-for-marketing-claims; monotherapy-paused state; compounded-source quality variability).

Step 5 — Pre-treatment workup (§3). Standard metabolic + organ-baseline + cagrilintide-specific bone-biology baseline DXA (postmenopausal). Body composition baseline DEXA.

Step 6 — Initiation (§4). 0.3 mg starting → 16-week titration → 2.4 mg weekly maintenance. Early monitoring cadence.

Step 7 — Maintenance (§5). Quarterly Y1 → biannual Y2+. Cagrilintide-specific bone-biology DXA at 24 months.

Step 8 — Branch points (§6 / §7 / §8). Anticipated AE profile per §6.2 GI class; bone-biology surveillance per §6.10 + §5.3. Non-response algorithm per §7.5 — if non-responsive at Month 9, the dominant transition pathway is CagriSema combo (§7.5 pathway 5a) or cross-class to tirzepatide (§7.5 pathway 5b).

Step 9 — Combination decisions (§9). No within-Module-5 combination at initiation (cagrilintide-monotherapy); lean-mass-stack consideration deferred unless §5.3 body-composition monitoring shows >25-30% lean-mass-loss proportion.

Step 10 — Counseling beats (§10). Initiation conversation per §10.2; compounded-source quality criteria per §10.3 + §10.6; pregnancy-planning not applicable (postmenopausal); comparator framing per §10.5 anchored at the access-pathway decision (Step 3).

Step 11 — Source citations (§11). All claims traced to §11.5 Bibliography subset: Lau 2021 PMID 34798060 + Garvey 2025 PMID 40544433 as the cagrilintide-monotherapy load-bearing anchors.

Step 12 — Verification gate (Appendix A). Cycle iteration documented.

Pattern Z calibration self-audit at §12.4. The decision-tree walkthrough presents the patient’s options factually with trial-anchored effect-size estimates; cagrilintide-monotherapy is framed as research-state-paused (Pattern Z.research-precision compliant); the CagriSema combo pathway is presented as the prioritized current-access pathway (Pattern AA precision); the compounded preparation pathway is framed at §10.3 pre-FDA-approval-compounding context; the patient’s mechanism-class preference (amylin alone vs amylin + GLP-1R) is patient-anchored; the comparator framing across all options is presented multi-dimensionally per Anchor 4; off-label / pre-approval transparency is explicit per Anchor 5; no Pattern Z violations observed.

---

Appendix A. Verification gate

The four-step verification cycle (production-agent draft → PSV agent → IAR agent → Dr. Gross gate) per Module 5 Protocol Template Appendix A. Cagrilintide-monotherapy protocol production iteration documented in /Process/Cagrilintide/Cagrilintide-Protocol-Production-Iteration-v1.md (to be created at PSV iteration 1 handoff).

Key PSV-iteration-1 verification scope for this protocol:

• PMID re-verification for §11.5 subset (Garvey 2025 PMID 40544433; Lau 2021 PMID 34798060; Enebo 2021 PMID 33894838; Andreasen 2020 PMID 32852869; Vrhovac Madunić 2022 PMID 35156012; Davies 2025 PMID 40544432; Parker 2025 PMID 40329607; Hathaway 2024 PMID 38958939; Lakhani 2025 PMID 40383360; Smith 2008 PMID 18753666; Aronne 2025 PMID 40353578; Wilding 2021 PMID 33567185; Jastreboff 2022 PMID 35658024; Lincoff 2023 PMID 37952131; Perkovic 2024 PMID 38785209; Sanyal 2025 PMID 40305708; Rubino 2021 PMID 33755728; Ko 2026 PMID 41359966; Singh-Franco 2011 PMID 21199269; Larsen 2023 PMID 36584289; Lau J 2021 PMID 34288673; Loomba 2024 PMID 38856224).
• NCT re-verification: NCT03856047 (Phase 2 dose-finding); NCT03600480 (Phase 1b combo); NCT05567796 (REDEFINE-1); NCT05394519 (REDEFINE-2); NCT05669755 (REDEFINE-3 CVOT — [[CagriSema Protocol]] scope); NCT05669781 (REDEFINE-4 East Asian — [[CagriSema Protocol]] scope); NCT05669742 (REDEFINE adolescent — [[CagriSema Protocol]] scope).
• Pattern AA.marketing-claims sweep: every “FDA-approved” reference precise per indication + sponsor + date.
• Pattern Z.research-precision sweep: no bias-vocabulary (“abandoned” / “failed” / “shelved” / “highly experimental” / “fringe”) describing cagrilintide-monotherapy development status.
• Pattern Z 5-anchor compliance verbatim-diff check against /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md.

IAR-iteration-1 scrutiny scope: six-axis scrutiny per Module 5 Protocol Template Appendix A.4 (framing, completeness, consistency, direction-of-effect, regulatory precision, identifier integrity); plus cagrilintide-specific scrutiny on (a) the cagrilintide-vs-CagriSema-combo cross-reference discipline (no cagrilintide-monotherapy claim incorrectly cites combo-arm effect; no combo-product claim incorrectly cites cagrilintide-alone effect); (b) the mechanism-class-specific bone-biology section §6.10 framing (mechanism-class research direction, not established signal); (c) the §10.6 Anchor 5 dominant subsection’s Pattern Z.research-precision discipline.

Dr. Gross gate: clinical-judgment review for the cagrilintide-monotherapy protocol’s voice / framing / tone alignment with the Voice Profile + the AC2-26 v2.4.2 + Editorial Framework v1.2.

---

Appendix B. Pattern discipline summary

B.1 Pattern R / R.1 / R.2 — framing discipline

§1 opens with what cagrilintide IS (long-acting amylin receptor agonist; CagriSema combo component) and with clinical-education framing — not with regulatory deficits. §2 opens with inclusion criteria. §6 opens with anticipatory framing per AE class. §7 opens with diagnostic distinctions. §8 opens with discontinuation triggers framed as legitimate clinical pathway. Section ordering locked at design-time.

B.2 Pattern V — direction-of-effect verification

Every effect-size claim anchored to primary source with population qualification. Cagrilintide-monotherapy approximately 11.8% at 68 weeks anchored to REDEFINE-1 cagrilintide-alone arm in non-diabetic obesity. Cagrilintide-monotherapy NAION-signal direction-of-effect research-state-uncharacterized — mechanism-class-distinct from GLP-1R class. Cagrilintide-mechanism-class bone-biology surveillance framed as mechanism-class research direction, not established signal.

B.3 Pattern W — cross-section enumeration consistency

Cagrilintide-monotherapy trial program comprises two principal trials (Phase 2 NCT03856047; Phase 3 REDEFINE-1 cagrilintide-alone arm NCT05567796) — locked at §1.2; reconciled across §3, §4, §5, §11, §12. CagriSema combo Phase 3 trial program (REDEFINE-1 combo arm; REDEFINE-2; REDEFINE-3; REDEFINE-4; REDEFINE adolescent) is consistently routed to [[CagriSema Protocol]] scope.

B.4 Pattern Z — 5-anchor calibration in §10

Anchor 1 (lead with what option IS); Anchor 2 (compounded vs FDA-approved adapted to pre-FDA-approval state per §10.3); Anchor 3 (pregnancy LEADS with Parker 2025 + cagrilintide-data-absence + pramlintide reference per §10.4); Anchor 4 (multi-dimensional comparator framing across 8+ dimensions per §10.5); Anchor 5 (off-label / extrapolation transparency DOMINANT per §10.6). §10.8 8-violation self-audit.

B.5 Pattern AA — regulatory-claim precision

Cagrilintide-monotherapy described as “investigational; monotherapy development paused; progressed primarily as CagriSema combo” — Pattern AA.marketing-claims precise. CagriSema combo described as “NDA filed with FDA per Novo Nordisk public disclosures; FDA approval pending.” Class-comparator regulatory states (semaglutide / tirzepatide / pramlintide) precise per indication + sponsor + label-date.

B.6 Pattern AB.1 / AB.2 / AB.4 — identifier-integrity standing scans

Pattern AB.1: production-agent identifier self-check at draft step — applied throughout §11.5. Pattern AB.2: PSV-agent mechanical re-verification — scope documented at Appendix A. Pattern AB.4: cascade scan — Bibliography subset inherits canonical Cagrilintide v1.0-final PSV iteration 1 verification (22/22 PMIDs + 7/7 NCTs verified).

B.7 Pattern N.1 — small-molecules path

Cagrilintide is a peptide (37-amino-acid acylated peptide; molecular weight approximately 4026 Da); structurally classified under Pattern N.1 as a peptide; protocol stored at /Peptides/Protocols/ path (within the peptides folder structure). Not a small-molecule.

B.8 Pattern AA.marketing-claims (new sub-pattern; added 2026-05-13)

Every regulatory-claim sentence in this protocol distinguishes (a) FDA-approved-for-marketing-claims (specific indication + sponsor + date), (b) anticipated-FDA-approval (NDA filed; FDA approval pending), (c) investigational (Phase 2 / Phase 3 status), (d) pre-FDA-approval-for-marketing-claims with monotherapy-paused state. Cagrilintide-monotherapy operates at (d); CagriSema combo operates at (b); class comparators operate at (a); investigational classes operate at (c).

B.9 Pattern Z.research-precision (new sub-pattern; added 2026-05-13)

Cagrilintide-monotherapy development status is described as paused / progressed primarily as combo / monotherapy Phase 3 not advanced. The protocol does NOT use abandoned / failed / shelved / highly experimental / fringe vocabulary anywhere. Pattern Z.research-precision is the vocabulary-level corollary to Pattern AA’s regulatory-state precision and to Pattern R’s lead-framing discipline.

B.10 Pattern discipline self-audit checklist

A protocol passes the full Pattern discipline audit when: Pattern R / R.1 / R.2 + Pattern V + Pattern W + Pattern Z (5 anchors) + Pattern Z.research-precision (no bias-vocabulary) + Pattern AA (regulatory-state precision) + Pattern AA.marketing-claims (FDA-approved-for-marketing-claims explicit precision) + Pattern AB.1 / AB.2 / AB.4 (identifier integrity) + Pattern N.1 (molecule classification correct). The cagrilintide-monotherapy protocol passes all per the §10.8 self-audit and the Appendix A.5 IAR-iteration-1 verification scope.

---

Appendix C. Self-audit findings

C.1 Pattern Z 5-anchor self-audit (§10.8 verification)

• Anchor 1 (lead with what option IS): §10.2 initiation conversation leads with “What cagrilintide-monotherapy IS” — long-acting amylin receptor agonist, mechanism-class-distinct, peer-reviewed evidence base. PASS.
• Anchor 2 (compounded vs FDA-approved): §10.3 leads with what compounded cagrilintide IS in the pre-FDA-approval state; operational differences framed factual-not-deficit; quality criteria framed as clinician-evaluation-supporting. Structurally parallel to Retatrutide protocol §10.3 pre-approval calibration. PASS.
• Anchor 3 (pregnancy LEADS with research-state): §10.4 LEADS with Parker 2025 PMID 40329607 GLP-1 RA pooled regulatory pregnancy data + acknowledgment of cagrilintide-specific data absence + pramlintide adjacent-class reference; PK arithmetic + class-level conservative-application AFTER the research-state lead. PASS.
• Anchor 4 (multi-dimensional comparator): §10.5 presents 10+ comparator dimensions (weight magnitude, regulatory status, mechanism class, CV outcomes, MASH approval, kidney outcomes, NAION class-differentiation, bone-biology mechanism-class-specific, hypoglycemia profile, GI tolerability, route, cost) across cagrilintide-monotherapy / CagriSema / semaglutide / tirzepatide / pramlintide. PASS.
• Anchor 5 (off-label / extrapolation transparency DOMINANT): §10.6 explicit off-label / pre-FDA-approval-for-marketing-claims framing; CagriSema combo pathway presented as prioritized current-access; compounded preparation and investigational supply pathways framed factually; Pattern Z.research-precision discipline (“paused” not “abandoned”). PASS.

C.2 Pattern AA.marketing-claims sweep

• Cagrilintide-monotherapy: “investigational; monotherapy development paused; progressed primarily as CagriSema combo” — every regulatory-state mention precise. PASS.
• CagriSema combo: “NDA filed per Novo Nordisk public disclosures; FDA approval pending; anticipated approval pending FDA review timelines” — every regulatory-state mention precise. PASS.
• Semaglutide: “FDA-approved (Wegovy CWM; Ozempic T2D + CV risk + CKD-in-T2D label expansion 2025; ESSENCE MASH F2/F3 label expansion 2025; Rybelsus 25 mg oral approved 2025)” — every reference precise. PASS.
• Tirzepatide: “FDA-approved (Mounjaro T2D; Zepbound CWM)” — precise. PASS.
• Pramlintide: “FDA-approved-for-marketing-claims for T1D / T2D insulin-adjunct indication (Symlin; AstraZeneca; FDA approved 2005)” — precise. PASS.

C.3 Pattern Z.research-precision sweep

Grep for bias-vocabulary across protocol body: “abandoned” → absent; “failed” → absent; “shelved” → absent; “highly experimental” → absent; “fringe” → absent; “unproven” → absent (only Phase 3-pending or research-state-incomplete framing used). PASS.

C.4 §11 PMID verification (canonical inheritance)

§11.5 Bibliography subset inherits canonical Cagrilintide v1.0-final PSV iteration 1 verification — Lau 2021 PMID 34798060 verified; Garvey 2025 PMID 40544433 verified; Enebo 2021 PMID 33894838 verified; Andreasen 2020 PMID 32852869 verified; Vrhovac Madunić 2022 PMID 35156012 verified. Class-comparator references inherit their respective canonical PSV verifications. PASS at canonical-inheritance level; PSV iteration 1 of this protocol re-verifies per Appendix A.

C.5 §9 CagriSema cross-reference discipline

§9 routes the within-Module-5 combination considerations to [[CagriSema Protocol]] for combo-product detail. Every CagriSema combo regulatory-state reference is Pattern AA.marketing-claims precise (NDA filed; FDA approval pending; cross-reference [[CagriSema Protocol]]). No cagrilintide-monotherapy claim incorrectly cites CagriSema combo-arm effect; no combo-product claim incorrectly cites cagrilintide-alone effect. PASS.

C.6 Dr. Gross items (anticipated handoff considerations)

• Voice / tone alignment. The protocol’s tone is clinical-education-reference voice, calibrated to the Voice Profile + Editorial Framework v1.2. Verify alignment at Appendix A.5 Dr. Gross gate.
• Cagrilintide-mechanism-class-specific bone-biology surveillance (§3.7 + §5.3 + §6.10). This is a mechanism-class-anchored research direction reflecting the calcitonin-receptor-heterodimer architecture; the framing is research-state-incomplete, not established-signal. Dr. Gross review for clinician-judgment posture appropriateness (baseline DXA + 24-month interval re-DXA + calcium / vitamin D adequacy).
• CagriSema combo cross-reference discipline (§9 + §10 + §12). The protocol heavily routes to [[CagriSema Protocol]] for combo-product detail; the cagrilintide-monotherapy track is documented for clinical-education completeness given the amylin-pathway scientific significance. Dr. Gross review for the routing-discipline appropriateness and for the relative weight of cagrilintide-monotherapy-specific content vs CagriSema-combo routing.
• Pattern Z.research-precision discipline. The protocol describes cagrilintide-monotherapy development as “paused” / “progressed primarily as combo” — factual research-state framing per the AC2-26 System Observations 2026-05-13 Pattern Z.research-precision sub-pattern. Dr. Gross review for vocabulary-discipline appropriateness across the protocol body.
• §10.3 compounded-cagrilintide framing. Structurally parallel to Retatrutide protocol §10.3 pre-approval calibration; not 503A/503B shortage-period framing. Dr. Gross review for Pattern Z anchor 2 calibration appropriateness in the pre-FDA-approval state.
• §10.5 comparator framing. 10+ dimensions including the cagrilintide-mechanism-class-specific bone-biology surveillance dimension (mechanism-class-distinct from GLP-1R / GIP / glucagon classes). Dr. Gross review for multi-dimensional fact presentation completeness and for any clinician-judgment dimensions missing from the comparator framework.
• §6.10 bone-biology mechanism-class research direction. Distinct from the GLP-1 RA class canonicals / protocols; mechanism-class basis is amylin-specific via calcitonin-receptor-heterodimer architecture. Dr. Gross review for clinical-experience alignment with the conservative-application clinician-judgment posture.

C.7 Word count and length-discipline

This protocol is approximately 17,500-19,000 words across the twelve sections and three appendices — within the 15,000-20,000 word target per the brief (shorter than the active-development class-comparator protocols given the monotherapy-paused state; longer than a placeholder skeleton given the scientific significance of the amylin pathway and the cagrilintide-specific bone-biology mechanism-class research direction).